WO2007002361A2 - 3-fluoro-piperidine t-type calcium channel antagonists - Google Patents

3-fluoro-piperidine t-type calcium channel antagonists Download PDF

Info

Publication number
WO2007002361A2
WO2007002361A2 PCT/US2006/024426 US2006024426W WO2007002361A2 WO 2007002361 A2 WO2007002361 A2 WO 2007002361A2 US 2006024426 W US2006024426 W US 2006024426W WO 2007002361 A2 WO2007002361 A2 WO 2007002361A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
substituted
fluoropiperidin
dimethylbutyl
phenyl
Prior art date
Application number
PCT/US2006/024426
Other languages
French (fr)
Other versions
WO2007002361A3 (en
Inventor
James C. Barrow
Craig W. Lindsley
William D. Shipe
Zhiqiang Yang
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to AU2006262101A priority Critical patent/AU2006262101A1/en
Priority to US11/922,390 priority patent/US20100222387A1/en
Priority to JP2008518415A priority patent/JP2008546800A/en
Priority to EP06773826A priority patent/EP1896414A4/en
Priority to CA002611153A priority patent/CA2611153A1/en
Publication of WO2007002361A2 publication Critical patent/WO2007002361A2/en
Publication of WO2007002361A3 publication Critical patent/WO2007002361A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • Plasma membrane calcium channels are members of a diverse superfamily of voltage gated channel proteins. Calcium channels are membrane-spanning, multi-subunit proteins that allow controlled entry of Ca2+ ions into cells from the extracellular fluid. Excitable cells throughout the animal kingdom, and at least some bacterial, fungal and plant cells, possess one or more types of calcium channel. Nearly all "excitable" cells in animals, such as neurons of the central nervous system (CNS), peripheral nerve cells and muscle cells, including those of skeletal muscles, cardiac muscles, and venous and arterial smooth muscles, have voltage-dependent calcium channels
  • calcium channels have been identified in mammalian cells from various tissues, including skeletal muscle, cardiac muscle, lung, smooth muscle and brain.
  • a major type of this family are the L-type calcium channels, whose function is inhibited by the familiar classes of calcium channel blockers (dihydropyridines such as nifedipine, phenylalkylamines such as verapamil, and benzothiazepines such as diltiazem).
  • Additional classes of plasma membrane calcium channels are referred to as T, N, P, Q and R.
  • the L, N, P and Q-type channels activate at more positive potentials (high voltage activated) and display diverse kinetics and voltage-dependent properties.
  • T-type calcium channels have been implicated in pathologies related to various diseases and disorders, including epilepsy, essential tremor, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, sleep disturbances, psychosis, schizophreniac, cardiac arrhythmia, hypertension, pain, cancer, diabetes, infertility and sexual dysfunction (J Neuroscience, 14, 5485 (1994); Drugs Future 30(6), 573-580 (2005); EMBO J, 24, 315-324 (2005); Drug Discovery Today, 11, 5/6, 245-253 (2006)).
  • the known therapeutic regimens for such treating such diseases and disorders suffer from numerous problems. Accordingly, a more physiological way to treat these diseases and disorders would be highly desirable.
  • the present invention is directed to 3-fluoro-piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which T-type calcium channels are involved.
  • the invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
  • Rl and R2 are independently selected from the group consisting of: (1) hydrogen, and
  • Ci-galkyl which is unsubstituted or substituted with halogen or hydroxyl, or Rl and R2 taken together form a C3-6cycloalkyl ring, which is unsubstituted or substituted with Ci-6alkyl or halogen, which is unsubstituted or substituted with Ci_6alkyl or halogen;
  • R3 is selected from the group consisting of:
  • Ci_8alkyl which is unsubstituted or substituted with one or more substituents selected from: (a) phenyl, which is substituted with R3a, R3b, R3C 5 R3d an d R3e ; (b) halogen,
  • R ⁇ and R* * are independently selected from hydrogen, - Ci-6alkyl and -Ci_6alkyl-O-Ci_6alkyl, or R 10 and R 1 * together form a pyrrolidine, piperidine, oxazolidine or morpholine ring, which is unsubstituted or substituted with halogen, Ci-galkyl or halogen-substituted Ci- ⁇ alkyl,
  • C3_iocycloalkyl which is unsubstituted or substituted with one or more substituents selected from: (a) phenyl, which is substituted with R3a, R3b ; R3C, R3d and R3e,
  • R3a ; R3b ; R3C 5 R3d and R ⁇ e are independently selected from the group consisting of:
  • R ⁇ and R ⁇ are independently selected from the group consisting of: (1) hydrogen,
  • Ci-8alkyl which is unsubstituted or substituted with one or more substituents selected from:
  • An embodiment of the present invention includes compounds of the formula I, wherein:
  • Rl and R2 are independently selected from the group consisting of:
  • R3 is selected from the group consisting of: (1) phenyl, which is substituted with R3a, R3b an d R3c,
  • C3_locycloalkyl which is unsubstituted or substituted with phenyl, where the phenyl is substituted with R3a, R3b an d R3C, an d (4) -Ci_6alkyl-(C3-iocycloalkyl), which is unsubstituted or substituted with phenyl, where the phenyl is substituted with R3a, R3b and R3C ;
  • R3a ? R3b an( j R3C a re independently selected from the group consisting of:
  • R4 and R5 are independently selected from the group consisting of: (1) hydrogen,
  • C]_8alkyl which is unsubstituted or substituted with hydroxy or phenyl, where the phenyl is substituted with R3a ; R3b an d R3C ;
  • An embodiment of the present invention includes compounds of the formula Ia':
  • An embodiment of the present invention includes compounds wherein R ⁇ is hydrogen and R ⁇ is hydrogen.
  • An embodiment of the present invention includes compounds wherein R3d is hydrogen and R3e is hydrogen.
  • An embodiment of the present invention includes compounds wherein R3 is phenyl which is substituted with R3a, R3b and R3C.
  • An embodiment of the present invention includes compounds wherein R3d is hydrogen, R3e is hydrogen, and R3a a R3b and R3c are independently selected from the group consisting of: (1) hydrogen,
  • An embodiment of the present invention includes compounds wherein R3 is adamantyl.
  • An embodiment of the present invention includes compounds wherein R3 is C4.
  • An embodiment of the present invention includes compounds wherein R3 is cyclobutyl- phenyl, where the phenyl is substituted with R? a , R3b and R3C.
  • An embodiment of the present invention includes compounds wherein R3 is cyclopentyl- phenyl, where the phenyl is substituted with R3a, R3b and R3c.
  • An embodiment of the present invention includes compounds wherein R3 is cyclohexyl- phenyl, where the phenyl is substituted with R3a ; R3b and R3C.
  • An embodiment of the present invention includes compounds wherein R4 is hydrogen.
  • An embodiment of the present invention includes compounds wherein R4 is hydrogen and R ⁇ is selected from the group consisting of:
  • Cl_8alkyl which is unsubstituted or substituted with hydroxy or phenyl, where the phenyl is substituted with R3a, R3b and R3c,
  • C 3 -iocycloalkyl which is unsubstituted or substituted with Ci-galkyl or phenyl, where the phenyl is substituted with R3a, R3b anc j R3C
  • C 3 _iocycloalkyloxy which is unsubstituted or substituted with Ci_8alkyl or phenyl, where the phenyl is substituted with R ⁇ a, R3b and R3c
  • An embodiment of the present invention includes compounds wherein R4 is hydrogen and R ⁇ is selected from the group consisting of:
  • An embodiment of the present invention includes compounds wherein R.4 is hydrogen and R5 is selected from the group consisting of:
  • Specific embodiments of the present invention include a compound which is selected from the group consisting of the subject compounds of the Examples herein or a pharmaceutically acceptable salt thereof.
  • the compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. The present invention is meant to comprehend all such isomeric forms of these compounds.
  • Formula I shows the structure of the class of compounds without preferred stereochemistry.
  • racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated.
  • the separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.
  • the coupling reaction is often the formation of salts using an enantiomerically pure acid or base.
  • the diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue.
  • the racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art.
  • any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.
  • halo or halogen as used herein are intended to include fluoro, chloro, bromo and iodo.
  • Ci-6alkyl is defined to identify the group as having 1, 2, 3, 4, 5 or 6 carbons in a linear or branched arrangement, such that Ci-galkyl specifically includes methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, pentyl, and hexyl.
  • a group which is designated as being independently substituted with substituents may be independently substituted with multiple numbers of such substituents.
  • heterocycle includes both unsaturated and saturated heterocyclic moieties, wherein the unsaturated heterocyclic moieties (termed “heteroaryl” herein) include benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyrazinyl,
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids.
  • Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylene- diamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
  • basic ion exchange resins such as
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
  • references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.
  • Exemplifying the invention is the use of the compounds disclosed in the Examples and herein.
  • Specific compounds within the present invention include a compound which selected from the group consisting of the compounds disclosed in the following Examples and pharmaceutically acceptable salts thereof and individual diastereomers thereof.
  • the subject compounds are useful in a method of antagonizing T-type calcium channel activity in a patient such as a mammal in need of such inhibition comprising the administration of an effective amount of the compound.
  • the present invention is directed to the use of the compounds disclosed herein as antagonists of T-type calcium channels activity. In addition to primates, especially humans, a variety of other mammals can be treated according to the method of the present invention.
  • the present invention is further directed to a method for the manufacture of a medicament for antagonizing T-type calcium channels activity or treating the disorders and diseases noted herein in humans and animals comprising combining a compound of the present invention with a pharmaceutical carrier or diluent.
  • the subject treated in the present methods is generally a mammal, preferably a human being, male or female.
  • the term "therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. It is recognized that one skilled in the art may affect the neurological and psychiatric disorders by treating a patient presently afflicted with the disorders or by prophylactically treating a patient afflicted with the disorders with an effective amount of the compound of the present invention.
  • treatment and “treating” refer to all processes wherein there may be a slowing, interrupting, arresting, controlling, or stopping of the progression of the neurological and psychiatric disorders described herein, but does not necessarily indicate a total elimination of all disorder symptoms, as well as the prophylactic therapy of the mentioned conditions, particularly in a patient who is predisposed to such disease or disorder.
  • administration of and or “administering a” compound should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to the individual in need thereof.
  • composition as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • Such term in relation to pharmaceutical composition is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • T-type calcium channel antagonists may be readily determined without undue experimentation by methodology well known in the art, including the "FLIPR Ca 2+ Flux Assay” and the “T-type Calcium (Ca 2+ ) Antagonist Voltage-Clamp Assay” [described by Xia,et al., Assay and Drug Development Tech., 1(5), 637-645 (2003)].
  • ion channel function from HEK 293 cells expressing the T-type channel alpha- IG, H, or I (CaV 3.1, 3.2, 3.3) is recorded to determine the activity of compounds in blocking the calcium current mediated by the T-type channel alpha-lG, H, or I (CaV 3.1, 3.2, 3.3).
  • calcium currents are elicited from the resting state of the human alpha-lG, H, or I (CaV 3.1, 3.2, 3.3) calcium channel as follows.
  • H3D5 growth media comprised DMEM, 6 % bovine calf serum (HYCLONE), 30 micromolar Verapamil, 200 microgram/ml Hygromycin B, IX Penicillin/ Streptomycin. Glass pipettes are pulled to a tip diameter of 1-2 micrometer on a pipette puller. The pipettes are filled with the intracellular solution and a chloridized silver wire is inserted along its length, which is then connected to the headstage of the voltage-clamp amplifier. Trypsinization buffer was 0.05 % Trypsin, 0.53 mM EDTA.
  • the extracellular recording solution consists of (mM): 130 mM NaCl, 4 mM KCl, ImM MgC12, 2mM CaC12, 10 mM HEPES, 30 Glucose, pH 7.4.
  • the internal solution consists of (mM): 135 mM CsMeSO4, 1 MgC12, 10 CsCl, 5 EGTA, 10 HEPES, pH 7.4, or 135 mM CsCl, 2 MgC12, 3 MgATP, 2 Na2ATP, 1 Na2GTP, 5 EGTA, 10 HEPES, pH 7.4.
  • the series resistance is noted (acceptable range is between 1-4 megaohm).
  • the junction potential between the pipette and bath solutions is zeroed on the amplifier.
  • Voltage protocols (1) -80 mV holding potential every 20 seconds pulse to -20 mV for 40 msec duration; the effectiveness of the drug in inhibiting the current mediated by the channel is measured directly from measuring the reduction in peak current amplitude initiated by the voltage shift from -80 mV to -20 mV; (2).
  • the intrinsic T-type calcium channel antagonist activity of a compound which may be used in the present invention may be determined by these assays.
  • the compounds of the following examples had activity in antagonizing the T-type calcium channel in the aforementioned assays, generally with an IC50 of less than about 10 ⁇ M.
  • Preferred compounds within the present invention had activity in antagonizing the T-type calcium channel in the aforementioned assays with an IC50 of less than about 1 ⁇ M. Such a result is indicative of the intrinsic activity of the compounds in use as antagonists of T-type calcium channel activity.
  • the present compounds exhibit unexpected properties, such as with respect to increased selectivity with respect to other receptors and/or ion channels.
  • T-type calcium channels have been implicated in a wide range of biological functions. This has suggested a potential role for these receptors in a variety of disease processes in humans or other species.
  • the compounds of the present invention have utility in treating, preventing, ameliorating, controlling or reducing the risk of a variety of neurological and psychiatric disorders associated with calcium channels, including one or more of the following conditions or diseases: movement disorders, including akinesias and akinetic-rigid syndromes (including Parkinson's disease, drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonism-ALS dementia complex and basal ganglia calcification), chronic fatigue syndrome, fatigue, including Parkinson's fatigue, multiple sclerosis fatigue, fatigue caused by a sleep disorder or a circadian rhythm disorder, medication-induced parkinsonism (such as neuroleptic- induced parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia,
  • the present invention provides methods for: treating, controlling, ameliorating or reducing the risk of epilepsy, including absence epilepsy; treating or controlling Parkinson's disease; treating essential tremor; treating or controlling pain, including neuropathic pain; enhancing the quality of sleep; augmenting sleep maintenance; increasing REM sleep; increasing slow wave sleep; decreasing fragmentation of sleep patterns; treating insomnia; enhancing cognition; increasing memory retention; treating or controlling depression; treating or controlling psychosis; or treating, controlling, ameliorating or reducing the risk of schizophrenia, in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of the present invention.
  • the subject compounds are further useful in a method for the prevention, treatment, control, amelioration, or reducation of risk of the diseases, disorders and conditions noted herein.
  • the dosage of active ingredient in the compositions of this invention may be varied, however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained.
  • the active ingredient may be administered to patients (animals and human) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy.
  • the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment.
  • the dose will vary from patient to patient depending upon the nature and severity of disease, the patient's weight, special diets then being followed by a patient, concurrent medication, and other factors which those skilled in the art will recognize. Generally, dosage levels of between 0.0001 to 10 mg/kg.
  • the dosage range will generally be about 0.5 mg to 1.0 g. per patient per day which may be administered in single or multiple doses.
  • the dosage range will be about 0.5 mg to 500 mg per patient per day; more preferably about 0.5 mg to 200 mg per patient per day; and even more preferably about 5 mg to 50 mg per patient per day.
  • Pharmaceutical compositions of the present invention may be provided in a solid dosage formulation preferably comprising about 0.5 mg to 500 mg active ingredient, more preferably comprising about 1 mg to 250 mg active ingredient.
  • the pharmaceutical composition is preferably provided in a solid dosage formulation comprising about 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg or 250 mg active ingredient.
  • the compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
  • the compounds of the present invention may be used in combination with one or more other drugs in the treatment, prevention, control, amelioration, or reduction of risk of diseases or conditions for which compounds of the present invention or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone.
  • Such other drug(s) may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention.
  • a pharmaceutical composition in unit dosage form containing such other drugs and the compound of the present invention is preferred.
  • the combination therapy may also includes therapies in which the compound of the present invention and one or more other drugs are administered on different overlapping schedules.
  • the compounds of the present invention and the other active ingredients may be used in lower doses than when each is used singly.
  • the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of the present invention.
  • the above combinations include combinations of a compound of the present invention not only with one other active compound, but also with two or more other active compounds.
  • compounds of the present invention may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which compounds of the present invention are useful.
  • Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention.
  • a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred.
  • the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of the present invention.
  • the weight ratio of the compound of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with another agent, the weight ratio of the compound of the present invention to the other agent will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1 :200. Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used. In such combinations the compound of the present invention and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
  • the compounds of the present invention may be employed in combination with an antiseizure agent such as carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, fosphenytoin, gabapentin, lamotrigine, levetiracetam, lorazepam, midazolam, oxcarbazepine, phenobarbital, phenytoin, primidone, tiagabine, topiramate, valproate, vigabatrin or zonisamide.
  • an antiseizure agent such as carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, fosphenytoin, gabapentin, lamotrigine, levetiracetam, lorazepam, midazolam, oxcarbazepine, phenobarbital, phenytoin, primidone, tiagabine, to
  • the subject compound may be employed in combination with acetophenazine, alentemol, benzhexol, bromocriptine, biperiden, chlorpromazine, chlorprothixene, clozapine, diazepam, fenoldopam, fluphenazine, haloperidol, levodopa, levodopa with benserazide, levodopa with carbidopa, lisuride, loxapine, mesoridazine, molindolone, naxagolide, olanzapine, pergolide, perphenazine, pimozide, pramipexole, risperidone, sulpiride, tetrabenazine, trihexyphenidyl, thioridazine, thiothixene, trifluoperazine or valproic acid.
  • the compounds of the present invention may be employed in combination with levodopa (with or without a selective extracerebral decarboxylase inhibitor such as carbidopa or benserazide), anticholinergics such as biperiden (optionally as its hydrochloride or lactate salt) and trihexyphenidyl (benzhexol) hydrochloride, COMT inhibitors such as entacapone, MOA-B inhibitors, antioxidants, A2a adenosine receptor antagonists, cholinergic agonists, serotonin receptor antagonists and dopamine receptor agonists such as alentemol, bromocriptine, fenoldopam, lisuride, naxagolide, pergolide and pramipexole.
  • levodopa with or without a selective extracerebral decarboxylase inhibitor such as carbidopa or benserazide
  • anticholinergics such as biperiden (optionally
  • the dopamine agonist may be in the form of a pharmaceutically acceptable salt, for example, alentemol hydrobromide, bromocriptine mesylate, fenoldopam mesylate, naxagolide hydrochloride and pergolide mesylate.
  • a pharmaceutically acceptable salt for example, alentemol hydrobromide, bromocriptine mesylate, fenoldopam mesylate, naxagolide hydrochloride and pergolide mesylate.
  • Lisuride and pramipexol are commonly used in a non-salt form.
  • the compounds of the present invention may be employed in combination with a compound from the phenothiazine, thioxanthene, heterocyclic dibenzazepine, butyrophenone, diphenylbutylpiperidine and indolone classes of neuroleptic agent.
  • phenothiazines include chlorpromazine, mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine and trifluoperazine.
  • Suitable examples of thioxanthenes include chlorprothixene and thiothixene.
  • An example of a dibenzazepine is clozapine.
  • An example of a butyrophenone is haloperidol.
  • An example of a diphenylbutylpiperidine is pimozide.
  • An example of an indolone is molindolone.
  • Other neuroleptic agents include loxapine, sulpiride and risperidone.
  • the neuroleptic agents when used in combination with the subject compound may be in the form of a pharmaceutically acceptable salt, for example, chlorpromazine hydrochloride, mesoridazine besylate, thioridazine hydrochloride, acetophenazine maleate, fluphenazine hydrochloride, flurphenazine enathate, fluphenazine decanoate, trifluoperazine hydrochloride, thiothixene hydrochloride, haloperidol decanoate, loxapine succinate and molindone hydrochloride.
  • Perphenazine, chlorprothixene, clozapine, haloperidol, pimozide and risperidone are commonly used in a non-salt form.
  • the compounds of the present invention may be employed in combination with an opiate agonist, a lipoxygenase inhibitor, such as an inhibitor of 5 -lipoxygenase, a cyclooxygenase inhibitor, such as a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as an interleukin- 1 inhibitor, an NMDA antagonist, an inhibitor of nitric oxide or an inhibitor of the synthesis of nitric oxide, a non-steroidal antiinflammatory agent, or a cytokine-suppressing antiinflammatory agent, for example with a compound such as acetaminophen, asprin, codiene, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sunlindac, tenidap, and the like.
  • a lipoxygenase inhibitor such as
  • the subject compound may be administered with a pain reliever; a potentiator such as caffeine, an H2-antagonist, simethicone, aluminum or magnesium hydroxide; a decongestant such as phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxy-ephedrine; an antitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextrametho ⁇ han; a diuretic; and a sedating or non-sedating antihistamine.
  • a pain reliever such as caffeine, an H2-antagonist, simethicone, aluminum or magnesium hydroxide
  • a decongestant such as phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephine
  • the subject compound may be employed in combination with an L-type calcium channel antagonist, such as amlodipine.
  • the compounds of the present invention may be administered in combination with compounds which are known in the art to be useful for enhancing sleep quality and preventing and treating sleep disorders and sleep disturbances, including e.g., sedatives, hypnotics, anxiolytics, antipsychotics, antianxiety agents, antihistamines, benzodiazepines, barbiturates, cyclopyrrolones, GABA agonists, 5HT-2 antagonists including 5HT-2A antagonists and 5HT-2A/2C antagonists, histamine antagonists including histamine H3 antagonists, histamine H3 inverse agonists, imidazopyridines, minor tranquilizers, melatonin agonists and antagonists, melatonergic agents, other orexin antagonists, orexin agonists, prokineticin agonists and antagonists, pyrazolopyrimidines, other T- type
  • the compounds of the present invention may be employed in combination with an anti-depressant or anti-anxiety agent, including norepinephrine reuptake inhibitors (including tertiary amine tricyclics and secondary amine tricyclics), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), corticotropin releasing factor (CRF) antagonists, ⁇ -adrenoreceptor antagonists, neurokinin- 1 receptor antagonists, atypical anti-depressants, benzodiazepines, 5-HTi A agonists or antagonists, especially 5-HT] A partial agonists, and corticotropin releasing factor (CRF) antagonists.
  • norepinephrine reuptake inhibitors including tertiary amine tricyclics and secondary amine tricycl
  • Specific agents include: amitriptyline, clomipramine, doxepin, imipramine and trimipramine; amoxapine, desipramine, maprotiline, nortriptyline and protriptyline; fluoxetine, fluvoxamine, paroxetine and sertraline; isocarboxazid, phenelzine, tranylcypromine and selegiline; moclobemide: venlafaxine; aprepitant; bupropion, lithium, nefazodone, trazodone and viloxazine; alprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam and prazepam; buspirone, flesinoxan, gepirone and ipsapirone, and pharmaceutically acceptable salts thereof.
  • the compounds of the present invention may be employed in combination with anti- Alzheimer's agents; beta-secretase inhibitors; gamma-secretase inhibitors; growth hormone secretagogues; recombinant growth hormone; HMG-CoA reductase inhibitors; NSAID's including ibuprofen; vitamin E; anti-amyloid antibodies; CB-I receptor antagonists or CB-I receptor inverse agonists; antibiotics such as doxycycline and rifampin; N-methyl-D-aspartate (NMDA) receptor antagonists, such as memantine; cholinesterase inhibitors such as galantamine, rivastigmine, donepezil, and tacrine; growth hormone secretagogues such as ibutamoren, ibutamoren mesylate, and capromorelin; histamine H3 antagonists; AMPA agonists; PDE IV inhibitors; GABAA inverse agonists; or neuronal nicotinic
  • the compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
  • parenteral e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant
  • inhalation spray nasal, vaginal, rectal, sublingual, or topical routes of administration
  • nasal, vaginal, rectal, sublingual, or topical routes of administration may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
  • the compounds of the invention are effective for
  • compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients.
  • the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • Pharmaceutical compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • compositions for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • Oily suspensions may be formulated by suspending the active ingredient in a suitable oil. Oil-in-water emulsions may also be employed.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • Pharmaceutical compositions of the present compounds may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • the compounds of the present invention may also be administered in the form of suppositories for rectal administration.
  • creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention may be employed.
  • the compounds of the present invention may also be formulated for administered by inhalation.
  • the compounds of the present invention may also be administered by a transdermal patch by methods known in the art.
  • Compound 1-1 is prepared as described by Liverton, N. J.; Claiborne, C. F.; Claremon, D. A.; McCauley, J. A. PCT int. Appl. (2004), WO 2004108705.
  • Acylation of 1-1 with either acid or acyl chloride produces the corresponding amide 1-2.
  • Removal of 4-methyl ben2yloxycarbonyl was achieved using HBr in acetic acid to give piperidine 1-3.
  • Reductive animation with an aldehyde or ketone affords compounds of the formula 1-4.
  • the final product may be further modified, for example, by manipulation of substituents.
  • substituents may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art.
  • the order of carrying out the foregoing reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products.
  • the following examples are provided so that the invention might be more fully understood. These examples are illustrative only and should not be construed as limiting the invention in any way.
  • the white precipitates were collected and washed with more diethyl ether and dried.
  • the above white solid (HBr salt, 0.2 g, 0.533 mmol) was mixed with NaBH(OAc) 3 ,(0.169 g, 0.799 mmol), dichloroethane (5 mL), diisopropylethylamine (0.176 mL, 1.07 mmol) and 3,3- dimethylbutyraldehyde (5.0 mL, 39.8 mmol). The resulting suspension was stirred at room temperature for overnight. The solvent was removed by concentration.
  • the crude aldehyde was mixed with the HBr salt of 3-F piperidine intermediate (see Example 2) (0.119g, 0.27 mmol), NaBH(OAc) 3 (0.114 g, 0.54 mmol) and triethylamine (0.075 mL, 0.54 mmol) in dichloroethane (3 mL). The resulting mixture was stirred at room temperature for overnight. The reaction was washed with sat. aqueous solution OfNaHCO 3 and brine, dried (Na 2 SO 4 ), filtered and cone.
  • the reaction was vented through a needle to a concentrated aqueous solution of NaOH. After stirring at room temperature for 15 minutes, LC-MS showed complete consumption of the starting material. Diethyl ether (100 mL) was then added to the reaction mixture. The precipitates were collected, washed with more diethyl ether and dissolved in H 2 O with the residue left in the reaction flask. The water solution was then transferred to a separatory funnel, and solid NaHCO 3 and CH 2 Cl 2 (100 mL) were added. After vigorously shaking, the two layers were separated. The water layers were extracted with CH 2 Cl 2 (> 3x) until LC-MS indicated that no product left.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention is directed to 3-fluoro-piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

Description

TITLE OF THE INVENTION
3-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS
BACKGROUND OF THE INVENTION Plasma membrane calcium channels are members of a diverse superfamily of voltage gated channel proteins. Calcium channels are membrane-spanning, multi-subunit proteins that allow controlled entry of Ca2+ ions into cells from the extracellular fluid. Excitable cells throughout the animal kingdom, and at least some bacterial, fungal and plant cells, possess one or more types of calcium channel. Nearly all "excitable" cells in animals, such as neurons of the central nervous system (CNS), peripheral nerve cells and muscle cells, including those of skeletal muscles, cardiac muscles, and venous and arterial smooth muscles, have voltage-dependent calcium channels
Multiple types of calcium channels have been identified in mammalian cells from various tissues, including skeletal muscle, cardiac muscle, lung, smooth muscle and brain. A major type of this family are the L-type calcium channels, whose function is inhibited by the familiar classes of calcium channel blockers (dihydropyridines such as nifedipine, phenylalkylamines such as verapamil, and benzothiazepines such as diltiazem). Additional classes of plasma membrane calcium channels are referred to as T, N, P, Q and R.
The "T-type" (or "low voltage-activated") calcium channels are so named because their openings are of briefer duration (T=transient) than the longer (L=long-lasting) openings of the L-type calcium channels. The L, N, P and Q-type channels activate at more positive potentials (high voltage activated) and display diverse kinetics and voltage-dependent properties. There are three subtypes of T- type calcium channels that have been molecularly, pharmacologically, and electrophysiologically identified from various warm blooded animals including rat [J Biol. Chem.276(6) 3999-4011 (2001); Eur J Neurosci 11(12):4171-8(1999); reviewed in Cell MoI Life Sci 56(7-8):660-9 (1999)]. These subtypes have been termed αlG, αlH, and all. The molecular properties of these channels demonstrate that the amino acid sequences are between 60-70% identical. The electrophysiological characterization of these individual subtypes has revealed differences in their voltage-dependent activation, inactivation, deactivation and steady-state inactivation levels and their selectivities to various ions such as barium (J Biol. Chem.276(6) 3999-4011 (2001)). Pharmacologically, these subtypes also have differing sensitivities to blockade by ionic nickel. These channel subtypes are also expressed in various forms due to their ability to undergo various splicing events during their assembly (J Biol. Chem.276(6) 3999-4011 (2001)).
T-type calcium channels have been implicated in pathologies related to various diseases and disorders, including epilepsy, essential tremor, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, sleep disturbances, psychosis, schizophreniac, cardiac arrhythmia, hypertension, pain, cancer, diabetes, infertility and sexual dysfunction (J Neuroscience, 14, 5485 (1994); Drugs Future 30(6), 573-580 (2005); EMBO J, 24, 315-324 (2005); Drug Discovery Today, 11, 5/6, 245-253 (2006)). The known therapeutic regimens for such treating such diseases and disorders suffer from numerous problems. Accordingly, a more physiological way to treat these diseases and disorders would be highly desirable.
SUMMARY OF THE INVENTION
The present invention is directed to 3-fluoro-piperidine compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
DETAILED DESCRIPTION OF THE INVENTION The present invention is directed to compounds of the formula I:
Figure imgf000003_0001
I wherein:
Rl and R2 are independently selected from the group consisting of: (1) hydrogen, and
(2) Ci-galkyl, which is unsubstituted or substituted with halogen or hydroxyl, or Rl and R2 taken together form a C3-6cycloalkyl ring, which is unsubstituted or substituted with Ci-6alkyl or halogen, which is unsubstituted or substituted with Ci_6alkyl or halogen;
R3 is selected from the group consisting of:
(1) phenyl, which is substituted with R3a, R3b, R3C, R3d and R3e,
(2) Ci_8alkyl, which is unsubstituted or substituted with one or more substituents selected from: (a) phenyl, which is substituted with R3a, R3b, R3C5 R3d and R3e; (b) halogen,
(c) hydroxyl,
(d) -O-Ci_6alkyl,
(e) -CO2R.9, where R^ is independently selected from: (i) hydrogen,
(ii) -Ci-βalkyl, which is nnsubstituted or substituted with 1-6 fluoro,
(iii) benzyl, and (iv) phenyl,
(f) -NRIORI 1, wherein R^ and R* * are independently selected from hydrogen, - Ci-6alkyl and -Ci_6alkyl-O-Ci_6alkyl, or R10 and R1 * together form a pyrrolidine, piperidine, oxazolidine or morpholine ring, which is unsubstituted or substituted with halogen, Ci-galkyl or halogen-substituted Ci-βalkyl,
(3) C3_iocycloalkyl, which is unsubstituted or substituted with one or more substituents selected from: (a) phenyl, which is substituted with R3a, R3b; R3C, R3d and R3e,
(b) halogen,
(c) hydroxyl,
(d) -O-Ci^alkyl,
(e) -CO2R9, (f) -NRlORl I5
(4) -Ci-6alkyl-(C3_iocycloalkyl), which is unsubstituted or substituted with one or more substituents selected from:
(a) phenyl, which is substituted with R3a, R3b5 R3C; R3d and R3e,
(b) halogen, (c) hydroxyl,
(d) -O-Ci-βalkyl,
(e) -CO2R9,
(f) -NRlORl 1,
(5) heteroaryl, which is substituted with R3^3 R3bs R3C; R3d an(j R3es Or oxo;
R3a; R3b; R3C5 R3d and R^e are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) hydroxyl, (4) -Ci-6alkyl,
(5) -O-Ci_6alkyl, (6) -CF3,
(7) -OCF3,
(8) -OCHF2,
(9) -OCH2F, (10) -OCF2CHF2,
(11) -CN, and
(12) -NRlORl I;
R^ and R^ are independently selected from the group consisting of: (1) hydrogen,
(2) Ci-8alkyl, which is unsubstituted or substituted with one or more substituents selected from:
(a) phenyl, which is substituted with R3a5 R3b; R3C, R3d and R3e,
(b) halogen, (c) hydroxyl,
(d) -O-Ci.6alkyl,
(e) -CO2R9,
(f) -NRIORH;
(3) C3_locycloalkyl, which is unsubstituted or substituted with one or more substituents selected from:
(a) phenyl, which is substituted with R3a, R3b, R3C, R3d and R3e,
(b) halogen,
(c) hydroxyl,
(d) -O-Ci-6alkyl, (e) -CO2R9,
(f) -NRl ORl I;
(4) phenyl, which is substituted with R3a, R3b, R3C, R3d and R3e;
(5) heterocycle, which is substituted with R3a, R3b; R3C3 R3d and R3e; Or oxo,
(6) -CO-Cl_8alkyl, which is unsubstituted or substituted with one or more substituents selected from:
(a) phenyl, which is substituted with R3a, R3b, R3C; R3d and R3e,3
(b) halogen,
(c) hydroxyl,
(d) -O-Ci_6alkyl,
Figure imgf000005_0001
(f) -NRl ORI I; (7) -SO2R9,
(8) -CO2R.9, and
(9) -CONRl ORI I, or R4 and R^ taken together form a C3_6cycloalkyl ring, which is unsubstituted or substituted with C 1 _βalkyl or halogen; and N-oxides thereof, and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
An embodiment of the present invention includes compounds of the formula I, wherein:
Rl and R2 are independently selected from the group consisting of:
(1) hydrogen, and
(2) Ci_6alkyl;
R3 is selected from the group consisting of: (1) phenyl, which is substituted with R3a, R3b and R3c,
(2) Cl -δalkyl, which is unsubstituted or substituted with phenyl, where the phenyl is substituted with R3a, R3b and R3c,
(3) C3_locycloalkyl, which is unsubstituted or substituted with phenyl, where the phenyl is substituted with R3a, R3b and R3C, and (4) -Ci_6alkyl-(C3-iocycloalkyl), which is unsubstituted or substituted with phenyl, where the phenyl is substituted with R3a, R3b and R3C; R3a? R3b an(j R3C are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen, (3) -Ci-6alkyl,
(4) -O-Ci_6alkyl,
(5) -CF3,
(6) -OCF3,
(7) -OCHF2, (8) -OCH2F,
(9) -OCF2CHF2,
(10) -CN, and
(11) -NRIORI 1, wherein R^ and R^ 1 are independently selected from hydrogen and -Ci- 6alkyl;
R4 and R5 are independently selected from the group consisting of: (1) hydrogen,
(2) C]_8alkyl, which is unsubstituted or substituted with hydroxy or phenyl, where the phenyl is substituted with R3a; R3b and R3C;
(3) Cs-iocycloalkyl, which is unsubstituted or substituted with Ci-galkyl or phenyl, where the phenyl is substituted with R3a, Rβb and R3c,
(4) Cs-iocycloalkyloxy, which is unsubstituted or substituted with Ci_8alkyl or phenyl, where the phenyl is substituted with R3a; R3b and R3c,
(5) -CO-Ci_8alkyl, and
(6) -CONRlORlI; and N-oxides thereof, and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
An embodiment of the present invention includes compounds of the formula Ia':
Figure imgf000007_0001
Ia1 wherein Rl , R2, R3, R4 and R5 are defined herein; or a pharmaceutically acceptable salt thereof or an individual enantiomer or diastereomer thereof.
An embodiment of the present invention includes compounds wherein R^ is hydrogen and R^ is hydrogen.
An embodiment of the present invention includes compounds wherein R3d is hydrogen and R3e is hydrogen.
An embodiment of the present invention includes compounds wherein R3 is phenyl which is substituted with R3a, R3b and R3C.
An embodiment of the present invention includes compounds wherein R3d is hydrogen, R3e is hydrogen, and R3aa R3b and R3c are independently selected from the group consisting of: (1) hydrogen,
(2) fluoro,
(3) chloro,
(4) bromo,
(5) -CH3, (6) -C(CH3)3, (7) -CF3,
(8) -CN,
(9) -0-CH3,
(10) -OCF3, (11) -OCHF2,
(12) -OCH2F,
(13) -OCF2CHF2, and
(14) -N(CH3)2.
An embodiment of the present invention includes compounds wherein R3 is adamantyl. An embodiment of the present invention includes compounds wherein R3 is C4.
6cycloalkyl-phenyl, where the phenyl is substituted with R^a, Rβb and R3C.
An embodiment of the present invention includes compounds wherein R3 is cyclobutyl- phenyl, where the phenyl is substituted with R?a, R3b and R3C.
An embodiment of the present invention includes compounds wherein R3 is cyclopentyl- phenyl, where the phenyl is substituted with R3a, R3b and R3c.
An embodiment of the present invention includes compounds wherein R3 is cyclohexyl- phenyl, where the phenyl is substituted with R3a; R3b and R3C.
An embodiment of the present invention includes compounds wherein R4 is hydrogen. An embodiment of the present invention includes compounds wherein R4 is hydrogen and R^ is selected from the group consisting of:
(1) Cl_8alkyl, which is unsubstituted or substituted with hydroxy or phenyl, where the phenyl is substituted with R3a, R3b and R3c,
(2) C3-iocycloalkyl, which is unsubstituted or substituted with Ci-galkyl or phenyl, where the phenyl is substituted with R3a, R3b ancj R3C, (3) C3_iocycloalkyloxy, which is unsubstituted or substituted with Ci_8alkyl or phenyl, where the phenyl is substituted with R^a, R3b and R3c, and
(4) -CO-Ci-salkyl, and
(5) -CONRlORl I.
An embodiment of the present invention includes compounds wherein R4 is hydrogen and R^ is selected from the group consisting of:
(1) Cl-galkyl, which is unsubstituted or substituted with hydroxy,
(2) C3_iocycloalkyl,
(3) -CO-Ci-galkyl,
(4) tetrahydrofuranyl, which is unsubstituted or substituted with one or more Cl_6alkyl, and (5) tetrahydropyranyl, which is unsubstituted or substituted with one or more Ci-galkyl. An embodiment of the present invention includes compounds wherein R.4 is hydrogen and R5 is selected from the group consisting of:
(1) -CH2CH2C(CH3)3,
(2) adamantyl, (3) dimethyl-tetrahydrofuranyl, and
(4) dimethyl-tetrahydropyranyl.
Specific embodiments of the present invention include a compound which is selected from the group consisting of the subject compounds of the Examples herein or a pharmaceutically acceptable salt thereof. The compounds of the present invention may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. The present invention is meant to comprehend all such isomeric forms of these compounds. Formula I shows the structure of the class of compounds without preferred stereochemistry.
The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.
If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography. The coupling reaction is often the formation of salts using an enantiomerically pure acid or base. The diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue. The racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art.
Alternatively, any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art. As appreciated by those of skill in the art, halo or halogen as used herein are intended to include fluoro, chloro, bromo and iodo. Similarly, C 1-6, as in Ci-6alkyl is defined to identify the group as having 1, 2, 3, 4, 5 or 6 carbons in a linear or branched arrangement, such that Ci-galkyl specifically includes methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, pentyl, and hexyl. A group which is designated as being independently substituted with substituents may be independently substituted with multiple numbers of such substituents. The term "heterocycle" as used herein includes both unsaturated and saturated heterocyclic moieties, wherein the unsaturated heterocyclic moieties (termed "heteroaryl" herein) include benzoimidazolyl, benzimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, and N-oxides thereof, and wherein the saturated heterocyclic moieties include azetidinyl, 1 ,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, tetrahydrofuranyl, thiomoφholinyl, and tetrahydrothienyl, and N-oxides thereof. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylene- diamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, fumaric, and tartaric acids. It will be understood that, as used herein, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts. Exemplifying the invention is the use of the compounds disclosed in the Examples and herein. Specific compounds within the present invention include a compound which selected from the group consisting of the compounds disclosed in the following Examples and pharmaceutically acceptable salts thereof and individual diastereomers thereof. The subject compounds are useful in a method of antagonizing T-type calcium channel activity in a patient such as a mammal in need of such inhibition comprising the administration of an effective amount of the compound. The present invention is directed to the use of the compounds disclosed herein as antagonists of T-type calcium channels activity. In addition to primates, especially humans, a variety of other mammals can be treated according to the method of the present invention. The present invention is further directed to a method for the manufacture of a medicament for antagonizing T-type calcium channels activity or treating the disorders and diseases noted herein in humans and animals comprising combining a compound of the present invention with a pharmaceutical carrier or diluent.
The subject treated in the present methods is generally a mammal, preferably a human being, male or female. The term "therapeutically effective amount" means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. It is recognized that one skilled in the art may affect the neurological and psychiatric disorders by treating a patient presently afflicted with the disorders or by prophylactically treating a patient afflicted with the disorders with an effective amount of the compound of the present invention. As used herein, the terms "treatment" and "treating" refer to all processes wherein there may be a slowing, interrupting, arresting, controlling, or stopping of the progression of the neurological and psychiatric disorders described herein, but does not necessarily indicate a total elimination of all disorder symptoms, as well as the prophylactic therapy of the mentioned conditions, particularly in a patient who is predisposed to such disease or disorder. The terms "administration of and or "administering a" compound should be understood to mean providing a compound of the invention or a prodrug of a compound of the invention to the individual in need thereof.
The term "composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. Such term in relation to pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The utility of the compounds in accordance with the present invention as T-type calcium channel antagonists may be readily determined without undue experimentation by methodology well known in the art, including the "FLIPR Ca2+ Flux Assay" and the "T-type Calcium (Ca2+) Antagonist Voltage-Clamp Assay" [described by Xia,et al., Assay and Drug Development Tech., 1(5), 637-645 (2003)]. In a typical experiment ion channel function from HEK 293 cells expressing the T-type channel alpha- IG, H, or I (CaV 3.1, 3.2, 3.3) is recorded to determine the activity of compounds in blocking the calcium current mediated by the T-type channel alpha-lG, H, or I (CaV 3.1, 3.2, 3.3). In this T-type calcium (Ca2+) antagonist voltage-clamp assay calcium currents are elicited from the resting state of the human alpha-lG, H, or I (CaV 3.1, 3.2, 3.3) calcium channel as follows. Sequence information for T- type (Low-voltage activated) calcium channels are fully disclosed in e.g., US 5,618,720, US 5,686,241, US 5,710,250,US 5,726,035, US 5,792,846, US 5,846,757, US 5,851,824, US 5,874,236, US 5,876,958, US 6,013,474, US 6,057,114, US 6,096,514, WO 99/28342, and J. Neuroscience, /P(6):1912-1921 (1999). Cells expressing the t-type channels were grown in H3D5 growth media which comprised DMEM, 6 % bovine calf serum (HYCLONE), 30 micromolar Verapamil, 200 microgram/ml Hygromycin B, IX Penicillin/ Streptomycin. Glass pipettes are pulled to a tip diameter of 1-2 micrometer on a pipette puller. The pipettes are filled with the intracellular solution and a chloridized silver wire is inserted along its length, which is then connected to the headstage of the voltage-clamp amplifier. Trypsinization buffer was 0.05 % Trypsin, 0.53 mM EDTA. The extracellular recording solution consists of (mM): 130 mM NaCl, 4 mM KCl, ImM MgC12, 2mM CaC12, 10 mM HEPES, 30 Glucose, pH 7.4. The internal solution consists of (mM): 135 mM CsMeSO4, 1 MgC12, 10 CsCl, 5 EGTA, 10 HEPES, pH 7.4, or 135 mM CsCl, 2 MgC12, 3 MgATP, 2 Na2ATP, 1 Na2GTP, 5 EGTA, 10 HEPES, pH 7.4. Upon insertion of the pipette tip into the bath, the series resistance is noted (acceptable range is between 1-4 megaohm). The junction potential between the pipette and bath solutions is zeroed on the amplifier. The cell is then patched, the patch broken, and, after compensation for series resistance ( >= 80%) , the voltage protocol is applied while recording the whole cell Ca2+ current response. Voltage protocols: (1) -80 mV holding potential every 20 seconds pulse to -20 mV for 40 msec duration; the effectiveness of the drug in inhibiting the current mediated by the channel is measured directly from measuring the reduction in peak current amplitude initiated by the voltage shift from -80 mV to -20 mV; (2). -100 mV holding potential every 15 seconds pulse to -20 mV for 40 msec duration; the effectiveness of the drug in inhibiting the current mediated by the channel is measured directly from measuring the reduction in peak current amplitude initiated by the shift in potential from -100 mV to -30 mV. The difference in block at the two holding potentials was used to determine the effect of drug at differing levels of inactivation induced by the level of resting state potential of the cells. After obtaining control baseline calcium currents, extracellular solutions containing increasing concentrations of a test compound are washed on. Once steady state inhibition at a given compound concentration is reached, a higher concentration of compound is applied. % inhibition of the peak inward control Ca2+ current during the depolarizing step to -20 mV is plotted as a function of compound concentration.
The intrinsic T-type calcium channel antagonist activity of a compound which may be used in the present invention may be determined by these assays.
In particular, the compounds of the following examples had activity in antagonizing the T-type calcium channel in the aforementioned assays, generally with an IC50 of less than about 10 μM.
Preferred compounds within the present invention had activity in antagonizing the T-type calcium channel in the aforementioned assays with an IC50 of less than about 1 μM. Such a result is indicative of the intrinsic activity of the compounds in use as antagonists of T-type calcium channel activity.
With respect to other piperidinyl compounds, the present compounds exhibit unexpected properties, such as with respect to increased selectivity with respect to other receptors and/or ion channels.
T-type calcium channels have been implicated in a wide range of biological functions. This has suggested a potential role for these receptors in a variety of disease processes in humans or other species. The compounds of the present invention have utility in treating, preventing, ameliorating, controlling or reducing the risk of a variety of neurological and psychiatric disorders associated with calcium channels, including one or more of the following conditions or diseases: movement disorders, including akinesias and akinetic-rigid syndromes (including Parkinson's disease, drug-induced parkinsonism, postencephalitic parkinsonism, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, parkinsonism-ALS dementia complex and basal ganglia calcification), chronic fatigue syndrome, fatigue, including Parkinson's fatigue, multiple sclerosis fatigue, fatigue caused by a sleep disorder or a circadian rhythm disorder, medication-induced parkinsonism (such as neuroleptic- induced parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic- induced acute akathisia, neuroleptic-induced tardive dyskinesia and medication-induced postural tremor), Gilles de Ia Tourette's syndrome, seizure disorders, epilepsy, and dyskinesias [including tremor (such as rest tremor, essential tremor, postural tremor and intention tremor), chorea (such as Sydenham's chorea, Huntington's disease, benign hereditary chorea, neuroacanthocytosis, symptomatic chorea, drug-induced chorea and hemiballism), myoclonus (including generalised myoclonus and focal myoclonus), tics (including simple tics, complex tics and symptomatic tics), restless leg syndrome and dystonia (including generalised dystonia such as iodiopathic dystonia, drug-induced dystonia, symptomatic dystonia and paroxymal dystonia, and focal dystonia such as blepharospasm, oromandibular dystonia, spasmodic dysphonia, spasmodic torticollis, axial dystonia, dystonic writer's cramp and hemiplegic dystonia); heart disease, abnormal heart rhythms and arrythmias, myocardial infarction, congestive heart failure, coronary heart disease, sudden death, stroke, sexual and reproductive dysfunction, such as impaired fertility, infertility, diseases or disorders where abnormal oscillatory activity occurs in the brain, including depression, migraine, neuropathic pain, Parkinson's disease, psychosis and schizophrenia, as well as diseases or disorders where there is abnormal coupling of activity, particularly through the thalamus; enhancing cognitive function; enhancing memory; increasing memory retention; increasing trained performance; increasing immune response; increasing immune function; hot flashes; night sweats; extending life span; schizophrenia; muscle-related disorders that are controlled by the excitation/relaxation rhythms imposed by the neural system such as cardiac rhythm and other disorders of the cardiovascular system; conditions related to proliferation of cells such as vasodilation or vasorestriction and blood pressure; cancer; cardiac arrhythmia; hypertension; congestive heart failure; conditions of the genital/urinary system; disorders of sexual function and fertility; adequacy of renal function; responsivity to anesthetics; sleep disorders, sleep disturbances, including enhancing sleep quality, improving sleep quality, increasing sleep efficiency, augmenting sleep maintenance; increasing the value which is calculated from the time that a subject sleeps divided by the time that a subject is attempting to sleep; improving sleep initiation; decreasing sleep latency or onset (the time it takes to fall asleep); decreasing difficulties in falling asleep; increasing sleep continuity; decreasing the number of awakenings during sleep; decreasing intermittent wakings during sleep; decreasing nocturnal arousals; decreasing the time spent awake following the initial onset of sleep; increasing the total amount of sleep; reducing the fragmentation of sleep; altering the timing, frequency or duration of REM sleep bouts; altering the timing, frequency or duration of slow wave (i.e. stages 3 or 4) sleep bouts; increasing the amount and percentage of stage 2 sleep; promoting slow wave sleep; enhancing EEG-delta activity during sleep; increasing the amount of Delta sleep early in the sleep cycle, increasing REM sleep late in the sleep cycle; decreasing nocturnal arousals, especially early morning awakenings; increasing daytime alertness; reducing daytime drowsiness; treating or reducing excessive daytime sleepiness; increasing satisfaction with the intensity of sleep; increasing sleep maintenance; idiopathic insomnia; sleep problems; insomnia, hypersomnia, idiopathic hypersomnia, repeatability hypersomnia, intrinsic hypersomnia, narcolepsy, interrupted sleep, sleep apnea, obstructive sleep apnea, wakefulness, nocturnal myoclonus, REM sleep interruptions, jet-lag, shift workers' sleep disturbances, dyssomnias, night terror, insomnias associated with depression, emotional/mood disorders, Alzheimer's disease or cognitive impairment, as well as sleep walking and enuresis, and sleep disorders which accompany aging; Alzheimer's sundowning; conditions associated with circadian rhythmicity as well as mental and physical disorders associated with travel across time zones and with rotating shift-work schedules, conditions due to drugs which cause reductions in REM sleep as a side effect; fibromyalgia; syndromes which are manifested by non-restorative sleep and muscle pain or sleep apnea which is associated with respiratory disturbances during sleep; conditions which result from a diminished quality of sleep; mood disorders, such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder, mood disorders due to a general medical condition, and substance-induced mood disorders; anxiety disorders including acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, panic attack, panic disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, specific phobia, substance-induced anxiety disorder and anxiety due to a general medical condition; acute neurological and psychiatric disorders such as cerebral deficits subsequent to cardiac bypass surgery and grafting, stroke, ischemic stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neuronal damage; Huntington's Chorea; amyotrophic lateral sclerosis; multiple sclerosis; ocular damage; retinopathy; cognitive disorders; idiopathic and drug-induced Parkinson's disease; muscular spasms and disorders associated with muscular spasticity including tremors, epilepsy, convulsions; cognitive disorders including dementia (associated with Alzheimer's disease, ischemia, trauma, vascular problems or stroke, HIV disease, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt- Jacob disease, perinatal hypoxia, other general medical conditions or substance abuse); delirium, amnestic disorders or age related cognitive decline; schizophrenia or psychosis including schizophrenia (paranoid, disorganized, catatonic or undifferentiated), schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition and substance-induced psychotic disorder; substance-related disorders and addictive behaviors (including substance-induced delirium, persisting dementia, persisting amnestic disorder, psychotic disorder or anxiety disorder; tolerance, dependence or withdrawal from substances including alcohol, amphetamines, cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine, sedatives, hypnotics or anxiolytics); attention deficit/hyperactivity disorder (ADHD); conduct disorder; migraine (including migraine headache); urinary incontinence; substance tolerance, substance withdrawal (including, substances such as opiates, nicotine, tobacco products, alcohol, benzodiazepines, cocaine, sedatives, hypnotics, etc.); psychosis; schizophrenia; anxiety (including generalized anxiety disorder, panic disorder, and obsessive compulsive disorder); mood disorders (including depression, mania, bipolar disorders); trigeminal neuralgia; hearing loss; tinnitus; neuronal damage including ocular damage; retinopathy; macular degeneration of the eye; emesis; brain edema; pain, including acute pain, chronic pain, severe pain, intractable pain, inflammatory pain, chronic inflammatory pain, neuropathic pain, chronic neuropathic pain, post-traumatic pain, bone and joint pain (osteoarthritis), repetitive motion pain, dental pain, cancer pain, myofascial pain (muscular injury, fibromyalgia), perioperative pain (general surgery, gynecological), chronic pain, neuropathic pain, posttraumatic pain, trigeminal neuralgia, migraine and migraine headache.
Thus, in preferred embodiments the present invention provides methods for: treating, controlling, ameliorating or reducing the risk of epilepsy, including absence epilepsy; treating or controlling Parkinson's disease; treating essential tremor; treating or controlling pain, including neuropathic pain; enhancing the quality of sleep; augmenting sleep maintenance; increasing REM sleep; increasing slow wave sleep; decreasing fragmentation of sleep patterns; treating insomnia; enhancing cognition; increasing memory retention; treating or controlling depression; treating or controlling psychosis; or treating, controlling, ameliorating or reducing the risk of schizophrenia, in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of the present invention. The subject compounds are further useful in a method for the prevention, treatment, control, amelioration, or reducation of risk of the diseases, disorders and conditions noted herein.
The dosage of active ingredient in the compositions of this invention may be varied, however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The active ingredient may be administered to patients (animals and human) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. The dose will vary from patient to patient depending upon the nature and severity of disease, the patient's weight, special diets then being followed by a patient, concurrent medication, and other factors which those skilled in the art will recognize. Generally, dosage levels of between 0.0001 to 10 mg/kg. of body weight daily are administered to the patient, e.g., humans and elderly humans, to obtain effective antagonism of T-type calcium channel. The dosage range will generally be about 0.5 mg to 1.0 g. per patient per day which may be administered in single or multiple doses. Preferably, the dosage range will be about 0.5 mg to 500 mg per patient per day; more preferably about 0.5 mg to 200 mg per patient per day; and even more preferably about 5 mg to 50 mg per patient per day. Pharmaceutical compositions of the present invention may be provided in a solid dosage formulation preferably comprising about 0.5 mg to 500 mg active ingredient, more preferably comprising about 1 mg to 250 mg active ingredient. The pharmaceutical composition is preferably provided in a solid dosage formulation comprising about 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg or 250 mg active ingredient. For oral administration, the compositions are preferably provided in the form of tablets containing 1.0 to 1000 milligrams of the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.
The compounds of the present invention may be used in combination with one or more other drugs in the treatment, prevention, control, amelioration, or reduction of risk of diseases or conditions for which compounds of the present invention or the other drugs may have utility, where the combination of the drugs together are safer or more effective than either drug alone. Such other drug(s) may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound of the present invention is preferred. However, the combination therapy may also includes therapies in which the compound of the present invention and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of the present invention and the other active ingredients may be used in lower doses than when each is used singly. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to a compound of the present invention. The above combinations include combinations of a compound of the present invention not only with one other active compound, but also with two or more other active compounds.
Likewise, compounds of the present invention may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which compounds of the present invention are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of the present invention is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of the present invention.
The weight ratio of the compound of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with another agent, the weight ratio of the compound of the present invention to the other agent will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1 :200. Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used. In such combinations the compound of the present invention and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
The compounds of the present invention may be employed in combination with an antiseizure agent such as carbamazepine, clonazepam, divalproex, ethosuximide, felbamate, fosphenytoin, gabapentin, lamotrigine, levetiracetam, lorazepam, midazolam, oxcarbazepine, phenobarbital, phenytoin, primidone, tiagabine, topiramate, valproate, vigabatrin or zonisamide. In another embodiment, the subject compound may be employed in combination with acetophenazine, alentemol, benzhexol, bromocriptine, biperiden, chlorpromazine, chlorprothixene, clozapine, diazepam, fenoldopam, fluphenazine, haloperidol, levodopa, levodopa with benserazide, levodopa with carbidopa, lisuride, loxapine, mesoridazine, molindolone, naxagolide, olanzapine, pergolide, perphenazine, pimozide, pramipexole, risperidone, sulpiride, tetrabenazine, trihexyphenidyl, thioridazine, thiothixene, trifluoperazine or valproic acid.
In another embodiment, the compounds of the present invention may be employed in combination with levodopa (with or without a selective extracerebral decarboxylase inhibitor such as carbidopa or benserazide), anticholinergics such as biperiden (optionally as its hydrochloride or lactate salt) and trihexyphenidyl (benzhexol) hydrochloride, COMT inhibitors such as entacapone, MOA-B inhibitors, antioxidants, A2a adenosine receptor antagonists, cholinergic agonists, serotonin receptor antagonists and dopamine receptor agonists such as alentemol, bromocriptine, fenoldopam, lisuride, naxagolide, pergolide and pramipexole. It will be appreciated that the dopamine agonist may be in the form of a pharmaceutically acceptable salt, for example, alentemol hydrobromide, bromocriptine mesylate, fenoldopam mesylate, naxagolide hydrochloride and pergolide mesylate. Lisuride and pramipexol are commonly used in a non-salt form.
In another embodiment, the compounds of the present invention may be employed in combination with a compound from the phenothiazine, thioxanthene, heterocyclic dibenzazepine, butyrophenone, diphenylbutylpiperidine and indolone classes of neuroleptic agent. Suitable examples of phenothiazines include chlorpromazine, mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine and trifluoperazine. Suitable examples of thioxanthenes include chlorprothixene and thiothixene. An example of a dibenzazepine is clozapine. An example of a butyrophenone is haloperidol. An example of a diphenylbutylpiperidine is pimozide. An example of an indolone is molindolone. Other neuroleptic agents include loxapine, sulpiride and risperidone. It will be appreciated that the neuroleptic agents when used in combination with the subject compound may be in the form of a pharmaceutically acceptable salt, for example, chlorpromazine hydrochloride, mesoridazine besylate, thioridazine hydrochloride, acetophenazine maleate, fluphenazine hydrochloride, flurphenazine enathate, fluphenazine decanoate, trifluoperazine hydrochloride, thiothixene hydrochloride, haloperidol decanoate, loxapine succinate and molindone hydrochloride. Perphenazine, chlorprothixene, clozapine, haloperidol, pimozide and risperidone are commonly used in a non-salt form.
In another embodiment, the compounds of the present invention may be employed in combination with an opiate agonist, a lipoxygenase inhibitor, such as an inhibitor of 5 -lipoxygenase, a cyclooxygenase inhibitor, such as a cyclooxygenase-2 inhibitor, an interleukin inhibitor, such as an interleukin- 1 inhibitor, an NMDA antagonist, an inhibitor of nitric oxide or an inhibitor of the synthesis of nitric oxide, a non-steroidal antiinflammatory agent, or a cytokine-suppressing antiinflammatory agent, for example with a compound such as acetaminophen, asprin, codiene, fentanyl, ibuprofen, indomethacin, ketorolac, morphine, naproxen, phenacetin, piroxicam, a steroidal analgesic, sufentanyl, sunlindac, tenidap, and the like. Similarly, the subject compound may be administered with a pain reliever; a potentiator such as caffeine, an H2-antagonist, simethicone, aluminum or magnesium hydroxide; a decongestant such as phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxy-ephedrine; an antitussive such as codeine, hydrocodone, caramiphen, carbetapentane, or dextramethoφhan; a diuretic; and a sedating or non-sedating antihistamine. In another embodiment, the subject compound may be employed in combination with an L-type calcium channel antagonist, such as amlodipine. In another embodiment, the compounds of the present invention may be administered in combination with compounds which are known in the art to be useful for enhancing sleep quality and preventing and treating sleep disorders and sleep disturbances, including e.g., sedatives, hypnotics, anxiolytics, antipsychotics, antianxiety agents, antihistamines, benzodiazepines, barbiturates, cyclopyrrolones, GABA agonists, 5HT-2 antagonists including 5HT-2A antagonists and 5HT-2A/2C antagonists, histamine antagonists including histamine H3 antagonists, histamine H3 inverse agonists, imidazopyridines, minor tranquilizers, melatonin agonists and antagonists, melatonergic agents, other orexin antagonists, orexin agonists, prokineticin agonists and antagonists, pyrazolopyrimidines, other T- type calcium channel antagonists, triazolopyridines, and the like, such as: adinazolam, allobarbital, alonimid, alprazolam, amitriptyline, amobarbital, amoxapine, armodafmil, APD- 125, bentazepam, benzoctamine, brotizolam, bupropion, busprione, butabarbital, butalbital, capromorelin, capuride, carbocloral, chloral betaine, chloral hydrate, chlordiazepoxide, clomipramine, clonazepam, cloperidone, clorazepate, clorethate, clozapine, conazepam, cyprazepam, desipramine, dexclamol, diazepam, dichloralphenazone, divalproex, diphenhydramine, doxepin, EMD-281014, eplivanserin, estazolam, eszopiclone, ethchlorynol, etomidate, fenobam, flunitrazepam, flurazepam, fluvoxamine, fluoxetine, fosazepam, gaboxadol, glutethimide, halazepam, hydroxyzine, ibutamoren, imipramine, indiplon, lithium, lorazepam, lormetazepam, LY-156735, maprotiline, MDL-100907, mecloqualone, melatonin, mephobarbital, meprobamate, methaqualone, methyprylon, midaflur, midazolam, modafmil, nefazodone, NGD-2-73, nisobamate, nitrazepam, nortriptyline, oxazepam, paraldehyde, paroxetine, pentobarbital, perlapine, perphenazine, phenelzine, phenobarbital, prazepam, promethazine, propofol, protriptyline, quazepam, ramelteon, reclazepam, roletamide, secobarbital, sertraline, suproclone, TAK-375, temazepam, thioridazine, tiagabine, tracazolate, tranylcypromaine, trazodone, triazolam, trepipam, tricetamide, triclofos, trifluoperazine, trimetozine, trimipramine, uldazepam, venlafaxine, zaleplon, zolazepam, zopiclone, Zolpidem, and salts thereof, and combinations thereof, and the like, or the compound of the present invention may be administered in conjunction with the use of physical methods such as with light therapy or electrical stimulation.
In another embodiment, the compounds of the present invention may be employed in combination with an anti-depressant or anti-anxiety agent, including norepinephrine reuptake inhibitors (including tertiary amine tricyclics and secondary amine tricyclics), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), corticotropin releasing factor (CRF) antagonists, α-adrenoreceptor antagonists, neurokinin- 1 receptor antagonists, atypical anti-depressants, benzodiazepines, 5-HTiA agonists or antagonists, especially 5-HT]A partial agonists, and corticotropin releasing factor (CRF) antagonists. Specific agents include: amitriptyline, clomipramine, doxepin, imipramine and trimipramine; amoxapine, desipramine, maprotiline, nortriptyline and protriptyline; fluoxetine, fluvoxamine, paroxetine and sertraline; isocarboxazid, phenelzine, tranylcypromine and selegiline; moclobemide: venlafaxine; aprepitant; bupropion, lithium, nefazodone, trazodone and viloxazine; alprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam and prazepam; buspirone, flesinoxan, gepirone and ipsapirone, and pharmaceutically acceptable salts thereof.
In another embodiment, the compounds of the present invention may be employed in combination with anti- Alzheimer's agents; beta-secretase inhibitors; gamma-secretase inhibitors; growth hormone secretagogues; recombinant growth hormone; HMG-CoA reductase inhibitors; NSAID's including ibuprofen; vitamin E; anti-amyloid antibodies; CB-I receptor antagonists or CB-I receptor inverse agonists; antibiotics such as doxycycline and rifampin; N-methyl-D-aspartate (NMDA) receptor antagonists, such as memantine; cholinesterase inhibitors such as galantamine, rivastigmine, donepezil, and tacrine; growth hormone secretagogues such as ibutamoren, ibutamoren mesylate, and capromorelin; histamine H3 antagonists; AMPA agonists; PDE IV inhibitors; GABAA inverse agonists; or neuronal nicotinic agonists.
The compounds of the present invention may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes of administration and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, monkeys, etc., the compounds of the invention are effective for use in humans. The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. Pharmaceutical compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. Compositions for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil. Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Oily suspensions may be formulated by suspending the active ingredient in a suitable oil. Oil-in-water emulsions may also be employed. Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Pharmaceutical compositions of the present compounds may be in the form of a sterile injectable aqueous or oleagenous suspension. The compounds of the present invention may also be administered in the form of suppositories for rectal administration. For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention may be employed. The compounds of the present invention may also be formulated for administered by inhalation. The compounds of the present invention may also be administered by a transdermal patch by methods known in the art.
Several methods for preparing the compounds of this invention are illustrated in the following Schemes and Examples. Starting materials are made according to procedures known in the art or as illustrated herein. The following abbreviations are used herein: Me: methyl; Et: ethyl; t-Bu: tert-buty\; Ar: aryl; Ph: phenyl; Bn: benzyl; Ac: acetyl; THF: tetrahydrofuran; DMSO: dimethylsulfoxide; EDC: N- (3-Dimethylaminopropyl)-N'-ethylcarbodiimide; Boc: tert-butyloxy carbonyl; Et3N: triethylamine; DCM: dichloromethane; DCE: dichloroethane; BSA: bovine serum albumin; TFA: trifluoracetic acid; DMF: N,N-dimethylformamide; SOCl2: thionyl chloride; CDI: carbonyl diimidazole; rt: room temperature; HPLC: high performance liquid chromatography. The compounds of the present invention can be prepared in a variety of fashions.
SCHEME 1
Figure imgf000022_0001
Compound 1-1 is prepared as described by Liverton, N. J.; Claiborne, C. F.; Claremon, D. A.; McCauley, J. A. PCT int. Appl. (2004), WO 2004108705. Acylation of 1-1 with either acid or acyl chloride produces the corresponding amide 1-2. Removal of 4-methyl ben2yloxycarbonyl was achieved using HBr in acetic acid to give piperidine 1-3. Reductive animation with an aldehyde or ketone affords compounds of the formula 1-4.
In some cases the final product may be further modified, for example, by manipulation of substituents. These manipulations may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art. In some cases the order of carrying out the foregoing reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products. The following examples are provided so that the invention might be more fully understood. These examples are illustrative only and should not be construed as limiting the invention in any way.
EXAMPLE l
Figure imgf000022_0002
N- { IY3 S ,4R)- 1-03 -dimethylbutyl)-3 -fluoropiperidin-4-yl]methyl } adamantane- 1 -carboxamide
To a solution of 4-methylbenzyl (3S,4R)-4-(ammomethyl)-3-fluoropiperidine-l- carboxylate hydrochloride (1.5 g, 4.7 mmol) in CH2Cl2 (15 mL) at room temperature was added 1 - admantyl carboxylic acid (0.94 g, 5.2 mmol), l-hydroxy-7-azabenzotriazole (0.77g, 5.7 mmol), l-(3- demethylaminopropyl)-3-ethylcarbodπmide hydrochloride (1.1 g, 5.7 mmol) and diisopropylethylamine (1.65 mL, 9.47 mmol). The resulting mixture was allowed to stir at room temperature for 3 h. LC-MS indicated that the reaction was completed. The residue was purified by silica gel flash chromatography (gradient, 0-16% MeOH in CH2Cl2) to give title compound as a white amorphous solid upon drying (11.8g, 2.1g, 98%). MS (ES): 443.4 [M+l]+. To a solution of the above intermediate (2.0 g, 4.52 mmol) in CH2Cl2 (10 mL) was added HBr in AcOH (33 wt%, 10 mL). After stirring at room temperature for 0.5 h, LC-MS showed complete consumption of the starting material. Diethyl ether was then added to the reaction mixture. The white precipitates were collected and washed with more diethyl ether and dried. The above white solid (HBr salt, 0.2 g, 0.533 mmol) was mixed with NaBH(OAc)3,(0.169 g, 0.799 mmol), dichloroethane (5 mL), diisopropylethylamine (0.176 mL, 1.07 mmol) and 3,3- dimethylbutyraldehyde (5.0 mL, 39.8 mmol). The resulting suspension was stirred at room temperature for overnight. The solvent was removed by concentration. The residue was purified by silica gel flash chromatography (gradient, 0-20% MeOH in CH2Cl2) to give title compound as a white solid upon drying (0.144 g, 71% overall). 1H NMR (400MHz, CDCl3): δ 5.92 (bs, IH), 4.68 (d, J= 48.7 Hz, IH), 3.37-3.21 (m, 3H), 2.96 (d, J= 11.4, IH), 2.42-2.29 (m, 2H), 1.14-1.91 (m, 2H), 1.84 (m, 6H), 1.76-1.63 (m, 8H), 1.54 (dd, J= 13.0, 3.1 Hz, IH), 1.47-1.38 (m, 2H), 0.90 (s, 9H). HRMS (ES) calcd for C23H39FN2O [M+l]+ :379.3119, found 379.3119.
EXAMPLE 2
Figure imgf000023_0001
3.5-Dichloro-N-(rr3S.4R)-l-(33-dimethylbutyl)-3-fluoropiperidin-4-vllmethvUbenzamide
To a solution of 4-methylbenzyl (3S,4R)-4-(aminomethyl)-3-fiuoro-piperidme-l- carboxylate hydrochloride (Liverton, N. J.; Claiborne, C. F.; Claremon, D. A.; McCauley, J. A., PCT Int. Appl WO2004108705 (2004)) (10.45 g, 32.99 mmol) in CH2Cl2 (31 mL) at 0 0C was added Et3N (13 mL, 99 mmol) and 3,5-dichlorobenzoyl chloride (5.5 mL, 38 mmol). The resulting mixture was allowed to stir at room temperature for 1 h. LC-MS indicated that the reaction was completed. To this mixture was then added HBr in AcOH (33 wt%, 50 mL). The reaction was vented through a needle to a concentrated aqueous solution of NaOH. After stirring at room temperature for 1 h, LC-MS showed complete consumption of the starting material. Diethyl ether (300 mL) was then added to the reaction mixture. The white precipitates were collected and washed with more diethyl ether. The white solid was transferred to a separatory funnel, and sat. aqueous solution OfNaHCO3 (300 mL) and CH2Cl2 (300 mL) were added. After vigorously shaking, the two layers were separated. The water layers were extracted with CH2Cl2 (> 3x) until LC-MS indicated that no product left. The combined organic layer was washed with brine, dried (NaSO4), filtered and cone. The white solid obtained (3-F piperidine intermediate) was then mixed with NaBH(OAc)3,(10.5 g, 49.5 mmol), dichloroethane (100 mL) and 3,3-dimethylbutyraldehyde (5.0 mL, 39.8 mmol). The resulting suspension was stirred at room temperature for overnight. The reaction was worked-up by adding sat. aqueous solution OfNaHCO3 and extracted with CH2Cl2. The combined organic layers were dried (Na2SO4), filtered and cone. The residue was purified by silica gel flash chromatography (gradient, 0-20% MeOH in CH2Cl2) to give title compound as a white solid upon drying (11.8g, 92% overall). 1H NMR (400MHz, CDC13): d 7.62 (m, 2H), 7.49 (m, IH), 6.40 (bs, IH), 4.78 (d, J = 51.1 Hz, IH), 3.62-3.39 (m, 2H), 3.27 (t, J= 11.5 Hz, IH), 2.99 (d, J= 11.0, IH), 2.43-2.30 (m, 2H), 2.17-1.97 (m, 2H), 2.00-1.87 (m, 1H),1.83-1.72 (m, IH), 1.64-1.60 (m, IH), 1.55-1.38 (m, 2H), 0.90 (s, 9H). HRMS (ES) calcd for C19H27Cl2FN2O [M]+ -.389.1557, found 389.1561.
EXAMPLE 3
Figure imgf000024_0001
3,5-dichloro-N-({(3S,4R)-l-[(3,3-dimethyltetrahydrofuran-2-yl)methyl]-3-fluoropiperidin-4- yl } methvDbenzamide
The compound (3,3-dimethyl-tetrahydro-furan-2-yl)-methanol (0.065 g, 0.5 mmol)
(Zaidlewicz, M.; Sarnowski, R. Heterocycles 1982, 75, 281-284.) was dissolved in CH2Cl2 (3 mL) and cooled to 0 0C. Dess-Martin periodinane (424 mg, 1.0 mmol) was added, and the resulting mixture was stirred at room temperature for 2 h. The reaction was worked-up by adding sat. aqueous solution of NaHSO3, and extracted with CH2Cl2. The combined organic layers were washed with brine, dried (Na2SO^, filtered and cone, to give the crude aldehyde as a clear oil. The crude aldehyde was mixed with the HBr salt of 3-F piperidine intermediate (see Example 2) (0.119g, 0.27 mmol), NaBH(OAc)3 (0.114 g, 0.54 mmol) and triethylamine (0.075 mL, 0.54 mmol) in dichloroethane (3 mL). The resulting mixture was stirred at room temperature for overnight. The reaction was washed with sat. aqueous solution OfNaHCO3 and brine, dried (Na2SO4), filtered and cone. The residue was purified by preparative HPLC (5 -> 95% CH3CNZH2O over 30min, 0.05% added TFA, Cl 8 SunFire 19x150 mm) to give title compound as a white solid upon drying (18.4 mg, 13%). 1H NMR (400MHz, CDCl3): δ 7.75-7.68 (m, 2H), 7.9-7.50 (m, IH), 4.98 (d, J= 46.0 Hz, IH), 3.62-3.39 (m, 2H), 3.99-3.72 (m, H), 3.59-3.31 (m, 4H), 2.95-2.60 (m, 2H), 2.40-2.20 (m, IH), 2.18-1.99 (m, 1H),1.95-1.65 (m, 3H), 1.08 (s, 3H), 0.88 (m, 3H), MS (ES) calcd for C20H28Cl2FN2O2 [M+l]+: 417.1, found 417.1. EXAMPLE 4
Figure imgf000025_0001
3-chloro-N-{[(3S,4R)-l-r3,3-dimethyl-2-oxobutyl)-3-fluoropiperidin-4-yl1methyl}-5-methoxybenzamide
To a solution of 4-methylbenzyl (3S,4R)-4-(aminomethyl)-3-fluoro-piperidine-l- carboxylate hydrochloride (Liverton, N. J.; Claiborne, C. F.; Claremon, D. A.; McCauley, J. A., PCT Int. Appl WO2004108705 (2004)) (1.5 g, 4.7 mmol) in CH2Cl2 (20 mL) at 0 0C was added 3-chloro-5- methoxylbenzoyl acid (0.97 g, 5.2 mmol), HOAt (0.77 g, 5.7 mmol), EDC (1.1 g, 5.7 mmol) and diisopropropylethylamine (1.6 mL, 9.5 mmol). The resulting mixture was allowed to stir at room temperature for 1 h. LC-MS indicated that the reaction was completed. Concentration to about 10 mL volume and to this mixture was then added HBr in AcOH (30 wt%, 15 mL). The reaction was vented through a needle to a concentrated aqueous solution of NaOH. After stirring at room temperature for 15 minutes, LC-MS showed complete consumption of the starting material. Diethyl ether (100 mL) was then added to the reaction mixture. The precipitates were collected, washed with more diethyl ether and dissolved in H2O with the residue left in the reaction flask. The water solution was then transferred to a separatory funnel, and solid NaHCO3 and CH2Cl2 (100 mL) were added. After vigorously shaking, the two layers were separated. The water layers were extracted with CH2Cl2 (> 3x) until LC-MS indicated that no product left. The combined organic layer was washed with brine, dried (NaSO4), filtered and cone. A potion of the crude product obtained (3-F piperidine intermediate, 0.20 g, 0.67 mmol) was then mixed with K2CO3 (0.28 g, 2.0 mmol), 1-bromopinacolone (0.14 mL, 1.0 mmol) in MeCN (2 mL) in a sealed a tube. The resulting mixture was heated at 80 0C for 12 hours. The reaction mixture was filtered and purified by preparative HPLC (5 -> 95% CH3CN/H2O over 3OnUn, 0.05% added TFA, C18 SunFire 19x150 mm) to give title compound as a white solid upon freeze-drying. 1H NMR (400MHz, CDC13): δ 7.30 (s, IH), 7.23 (s, IH), 7.16 (bs, IH), 7.01 (t, J= 2.0 Hz, IH), 5.01 (d, J= 46.1 Hz, IH), 4.34 (d, J= 18.0 Hz, IH), 4.21 (d, J= 17.9 Hz, IH), 3.81 (s, 3H), 3.80 (t, J= 11.8 Hz, IH), 3.58-3.52 (m, 3H), 3.45 (dd, J= 28.7, 13.6 Hz, IH), 3.33 (dd, J= 12.3, 11.5 Hz, IH), 2.43-2.27 (m, IH), 2.05 (q, J= 11.9 Hz, IH), 1.89 (d, J= 12.5 Hz), 1.18 (s, 9H). HRMS (ES) calcd for C20H28ClFN2O3 [M+l]+ :399.1845, found 399.1849.
EXAMPLE 5
Figure imgf000026_0001
3-chloro-N-(ff3S.4R)-3-fluoro-l-rf2SV2-hvdroxy-3J-dimethylbu1yllpiperidin-4-vnmethylV5- methoxybenzamide and S-chloro-N-CKSSΛRVB-fluoro-l-fCZRVZ-hvdroxy-S^-dimethylbutyllpiperidin-^ yl I methyD-5 -methoxybenzamide To a solution of 3-chloro-N-{[(3S,4R)-l-(3,3-dimethyl-2-oxobutyl)-3-fluoropiperidin-4- yl]methyl}-5-methoxybenzamide (0.132 g, 0.331 mmol) in MeOH (1 mL) was added NaBH4 (0.0380 g, 0.993 mmol). The mixture was stirred at room temperature for 15 minutes. The solvent was removed and the residue was purified by preparative HPLC (5 -> 95% CH3CN/H2O over 30min, 0.05% added TFA, Cl 8 SunFire 19x150 mm) to give title compound as a white solid upon freeze-drying. HRMS (ES) calcd for C20H30ClFN2O3 [M+l]+: 401.2002, found 401.2011. The two diastereomers were separated on a chiral column (85% CO2, 15% MeOH with lmL/L of diethylamine as modifier, Chiralcel OJ, 2x25 cm, lOμO.'H NMR (400MHz, CDCl3, lnd peak): δ 7.26 (m, IH), 7.22 (m, IH), 7.03 (t, J= 1.8 Hz, IH), 6.36 (bs, IH), 4.74 (d, J= 48.9 Hz, IH), 3.84 (s, 3H), 3.57-3.43 (m, 2H), 3.36 (dd, J= 11.0, 3.1 Hz, IH), 3.14 (d, J= 12.6 Hz, IH), 3.10 (dd, J= 11.4, 10.3 Hz, IH), 2.46 (dd, J= 37.9, 12.6 Hz, IH), 2.36 (dd, J= 12.1, 2.6 Hz, IH), 2.26 (dd, J= 12.1, 11.0 Hz, IH), 2.07-1.90 (m, 2H), 1.74-1.55 (m, 2H), 0.90 (s, 9H). 1HNMR (400MHz, CDCl3, 2nd peak): δ 7.26 (m, IH), 7.22 (m, IH), 7.02 (t, J= 2.0 Hz, IH), 6.47 (bs, IH), 4.73 (d, J= 48.3 Hz, IH), 3.84 (s, 3H), 3.56-3.43 (m, 2H), 3.34-3.29 (m, 2H), 2.85 (d, J= 11.5 Hz, IH), 2.40 (t, J= 11.0 Hz, IH), 2.37 (d, J= 7.2 Hz, 2H), 2.12 (dd, J = 38.0, 12.8 Hz, IH), 2.05-1.90 (m, IH), 1.78 (dq, J= 12.3, 3.9Hz, IH), 1.62 (dd, J= 13.1, 3.1 Hz, IH), 0.90 (s, 9H).
EXAMPLE 6
Figure imgf000026_0002
N-r(f3S,4R)-l-[2-Ctert-butylamino)-2-oxoethyll-3-fluoropiperidin-4-yl|methyl)-3,5-dichlorobenzamide To a solution of tert-butylamine (1.0 ml, 9.5 mmol) and Et3N(1.3 ml, 9.5 mmol) in CH2Cl2 at 0 0C was added chloroacetyl chloride (0.758 ml, 9.516 mmol) dropwise. The reaction mixture was stirred at 0 0C for 15 min, and washed with 1.0 N HCl, water and brine. The organic layer was dried over Na2SO4 and filtered. The filtrate was concentrated to give 1.1 g of tan-colored solid as the crude intermediate 1. It was used without further purification. To a solution of 4-methylbenzyl (3S,4R)-4- (aminomethyl)-3-fluoro-piperidine-l-carboxylate hydrochloride (Liverton, N. J.; Claiborne, C. F.; Claremon, D. A.; McCauley, J. A., PCT Int. Appl WO2004108705 (2004)) (3.2 g, 10 mmol) and diisopropylethylamine (3.5 ml, 21 mmol) in 50 ml Of CH2Cl2 at 0 0C was added 3,5-dichloro benzoyl chloride (2.2 g, 10 mmol) in 10 ml Of CH2Cl2. The resulting mixture was stirred for 1 h, and LC-MS showed a good conversion. HBr in AcOH (33% wt) (4.8 ml, 80 mmol) was added slowly with a NaOH (40% aqueous solution) trap for the HBr gas released. After stirred at RT for 1 h, the reaction was complete as judged by LC-MS. The reaction mixture was poured into 100 ml OfEt2O. A tan-colored solid precipitated and collected by filtration. The solid was washed with Et2O and dried give a tan- colored solid as the crude product. Purification by silica gel column (0-10% MeOH in CH2Cl2, 20 min. gradient) gave 2.1 g (70% yield) of white solid as the desired intermediate 2.
A mixture of the intermediate 1 (11 mg, 0.072 mmol), intermediate 2 (23 mg, 0.072 mmol), and diisopropylethylamine (0.012 ml, 0.072 mmol) in 0.5 ml of dry DMF was stirred at RT overnight. LC-MS showed the reaction was complete. The reaction mixture was washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified using preparative HPLC (5 -> 95% CH3CN/H2O over 30min, 0.05% added TFA, C18 SunFire 19x150 mm) to afford 23 mg (77%) of the title compound. 1H NMR (CDCl3, 400 MHz) δ 7.81 (d, J= 1.0 Hz, 2H); 7.66 (t, J= 1.9 Hz3 IH); 5.07 (d, J= 46.0 Hz, IH); 3.95 (br d, J= 10.1Hz, IH); 3.84 (br s, 2H); 3.53 (br s, IH); 3.47 (d, J= 6.41 Hz, 2H); 3.36 (br s, IH); 3.33 (br d, J= 16.8 Hz, IH); 2.2 (m, IH); 1.98 (br d, J= 11.3 Hz, 2H); 1.37 (s, 9H); HRMS (ES) calcd for C19H27Cl2FN3O3 [M+lf :418.1459, found 418.1467.
TABLE l
The following compounds were prepared using the foregoing methodology, but substituting the appropriately substituted reagent, such as organometallic or amine, as described in the foregoing examples. The requisite starting materials were commercialy available, described in the literature or readily synthesized by one skilled in the art of organic synthesis without undue experimentation.
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
3-chloro-N-{[(3S,4R)-l-(3,3- dimethylbutyl)-3-fluoropiperidin-4- yljmethyl} -5-methylbenzamide
403.1 3-chloro-N-{[(3S,4R)-l-(3,3- dimethylbutyl)-3-fluoropiperidin-4- yl]methyl}-5-(fluoromethoxy)benzamide
401.1 3-chloro-N~({(3S,4R)-3-fluoro~l-[(2R)-2- hydroxy-3 ,3 -dimethylbutyl]piperidin-4- yl } nαethyl)-5 -methoxybenzamide
401.1 3-chIoro-N-({(3S,4R)-3-fluoro~l-[(2S)-2- hydroxy-3 ,3 -dimethylbutyl]piperidin-4- yl}methyl)-5-methoxybenzamide
Figure imgf000037_0001
- 36 - 399.1 3-chloro-N-{[(3S,4R)-l-(3,3-dimethyl-2- oxobutyl)-3-fluoropiperidin-4-yl]methyl}-
5-methoxybenzamide
373.1 4-chloro-N-{[(3S,4R)-l-(3,3- dimethylbutyl)-3-fluoropiperidin-4- yl]methyl } -3 -fluorobenzamide
405.1 3,5~dichloro-N-({(3S,4R)-3-fluoro-l- [(2R)-2-hydroxy-3,3- dimethylbutyl]piperidin-4- yl } methyl)benzamide
405.1 3,5-dichloro-N-({(3S,4R)-3-fluoro-l- [(2S)-2-hydroxy-3,3- dimethylbutyl]piperidin-4- yl}methyl)benzamide
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made without departing from the spirit and scope of the invention.

Claims

WHAT IS CLAIMED IS:
1. A compound of the formula I:
Figure imgf000042_0001
I wherein: Rl and R2 are independently selected from the group consisting of:
(1) hydrogen, and
(2) Ci-βalkyl, which is unsubstituted or substituted with halogen or hydroxyl, or Rl and R2 taken together form a C3_6cycloalkyl ring, which is unsubstituted or substituted with Ci-6alkyl or halogen;
R3 is selected from the group consisting of:
(1) phenyl, which is substituted with R3a, RSb, R3C; R3d and R3e, (2) Ci_galkyl, which is unsubstituted or substituted with one or more substituents selected from:
(a) phenyl, which is substituted with R3a, R3b; R3ca R3d and R3e;
(b) halogen,
(c) hydroxyl, (d) -O-Ci-6alkyl,
(e) -CC>2R9, where R^ is independently selected from:
(i) hydrogen,
(ii) -Ci_6alkyl, which is unsubstituted or substituted with 1-6 fluoro,
(iii) benzyl, and (iv) phenyl,
(f) -NRl ORI 1, wherein R^ and R^ 1 are independently selected from hydrogen, -Ci_6alkyl and -Ci_6alkyl-O-Ci_6alkyl, or R10 and R1 1 together form a pyrrolidine, piperidine, oxazolidine or morpholine ring, which is unsubstituted or substituted with halogen, Ci-βalkyl or halogen-substituted Ci-6alkyl, (3) C3-10cycloalkyl, which is unsubstituted or substituted with one or more substituents selected from:
(a) phenyl, which is substituted with Rβa, R3b, R3C, R3d and R3e,
(b) halogen, (c) hydroxyl,
(d) -O-Ci-βalkyl,
(e) -CO2R9,
(f) -NRIORI I,
(4) -Ci-6alkyl-(C3-iocycloalkyl); which is unsubstituted or substituted with one or more substituents selected from:
(a) phenyl, which is substituted with R3a, R3b5 RSc3 R3d and R3e,
(b) halogen,
(c) hydroxyl,
(d) -O-Ci_6alkyl,
Figure imgf000043_0001
(f) -NRlORlI3
(5) heteroaryl, which is substituted with R3a, R3b5 R3C, R3d and R3e, Or oxo;
R3as R3b; R3C5 R3d and R3e are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) hydroxyl,
(4) -Ci-6alkyl,
(5) -O-Ci_6alkyl,
(6) -CF3,
(7) -OCF3,
(8) -OCHF2,
(9) -OCH2F,
(10) -OCF2CHF2,
(11) -CN, and
(12) -NRlORlI;
R4 and R^ are independently selected from the group consisting of:
(1) hydrogen, (2) Ci-galkyl, which is unsubstituted or substituted with one or more substituents selected from: (a) phenyl, which is substituted with R3a, R3b; R3C5 R3d and R3e,
(b) halogen,
(c) hydroxyl,
(d) -O-Ci_6alkyl, (e) -CO2R9,
(f) -NRl ORI I; (3) C3-iocycloalkyl, which is unsubstituted or substituted with one or more substituents selected from:
(a) phenyl, which is substituted with R3a, R3b, R3ca R3d and R3e; (b) halogen,
(c) hydroxyl,
(d) -O-Ci_6alkyl,
(e) -CO2R9,
(f) -NRlORl 1; (4) phenyl, which is substituted with R3a? R3b; R3C; R3d and R3e;
(5) heterocycle, which is substituted with R3a; R3b; R3C; R3d and R3e, Or oxo,
(6) -CO~Ci-8alkyl, which is unsubstituted or substituted with one or more substituents selected from:
(a) phenyl, which is substituted with R3a, R3b; R3C5 R3d and R3ej5 (b) halogen,
(c) hydroxyl,
(d) -O-Ci_6alkyl,
(e) -CO2R9,
(f) -NRlORl I; (7) -SO2R9,
(8) -CO2R9, and
(9) -CONRlORl I, or R4 and R5 taken together form a C3_6cycloalkyl ring, which is unsubstituted or substituted with Ci_6alkyl or halogen; and N-oxides thereof, and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
2. The compound of Claim 1 wherein:
Rl and R2 are independently selected from the group consisting of: (1) hydrogen, and
(2) Ci-6alkyl; R3 is selected from the group consisting of:
(1) phenyl, which is substituted with Rβa, R3b and R3c3
(2) Cl_8alkyl, which is unsubstituted or substituted with phenyl, where the phenyl is substituted with R3a, R3b and R3C, (3) C3-iocycloalkyl, which is unsubstituted or substituted with phenyl, where the phenyl is substituted with R3a, R3b and R3c, and (4) -Ci-6alkyl-(C3_iocycloalkyl), which is unsubstituted or substituted with phenyl, where the phenyl is substituted with R3a, R3b and R3C;
R3as R3b and R3c are independently selected from the group consisting of: (1) hydrogen,
(2) halogen,
(3) -Ci-βalkyl,
(4) -O-Ci_6alkyl,
(5) -CF3, (6) -OCF3,
(7) -OCHF2,
(8) -OCH2F,
(9) -OCF2CHF2,
(10) -CN, and (11) -NRIORI 1, wherein R10 and R1 * are independently selected from hydrogen and -Ci- βalkyl; R4 and R5 are independently selected from the group consisting of:
(1) hydrogen,
(2) Cl_8alkyl, which is unsubstituted or substituted with hydroxy or phenyl, where the phenyl is substituted with R3a, R3b and R3C,
(3) C3_iocycloalkyl, which is unsubstituted or substituted with Ci_8alkyl or phenyl, where the phenyl is substituted with R3a, R3b and R3C,
(4) C3_iocycloalkyloxy, which is unsubstituted or substituted with Ci_8alkyl or phenyl, where the phenyl is substituted with R3a, R3b and R3C; and (5) -CO-C i_8alkyl, and
(6) -CONRIORH ; and N-oxides thereof, and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.
3. The compound of Claim 1 of the formula Ia':
Figure imgf000046_0001
Ia' or a pharmaceutically acceptable salt thereof or an individual enantiomer or diastereomer thereof.
4. The compound of Claim 1 wherein R* is hydrogen and R^ is hydrogen.
5. The compound of Claim 1 wherein R3 is phenyl which is substituted with R3a? R3b and R3c.
6. The compound of Claim 5 wherein R3a, R3b an{i R3C are independently selected from the group consisting of:
(1) hydrogen,
(2) fluoro,
(3) chloro,
(4) bromo,
(5) -CH3,
(6) -C(CH3)3,
(7) -CF3,
(8) -CN,
(9) -0-CH3,
(10) -OCF3,
(H) -OCHF2,
(12) -OCH2F,
(13) -OCF2CHF2, and
(14) -N(CH3)2.
7. The compound of Claim 1 wherein R3 is adamantyl.
8. The compound of Claim 1 wherein R3 is Czμόcycloalkyl-phenyl, where the phenyl is substituted with R3a, R3b and R3c.
9. The compound of Claim 1 wherein R3 is cyclobutyl-phenyl, where the phenyl is substituted with R3a, R3b and R3c.
10. The compound of Claim 1 wherein R3 is cyclopentyl-phenyl, where the phenyl is substituted with R3a, R3b and R3c.
11. The compound of Claim 1 wherein R3 is cyclohexyl-phenyl, where the phenyl is substituted with R3a, R3b and R3C.
12. The compound of Claim 2 wherein R4 is hydrogen.
13. The compound of Claim 12 wherein R4 is hydrogen and R^ is selected from the group consisting of: (1) Ci-galkyl, which is unsubstituted or substituted with hydroxy or phenyl, where the phenyl is substituted with R3a, R3b and R3c,
(2) C3_iocycloalkyl, which is unsubstituted or substituted with Ci-salkyl or phenyl, where the phenyl is substituted with R3a? R3b and R3c, and
(3) C3-iocycloalkyloxy, which is unsubstituted or substituted with Ci_8alkyl or phenyl, where the phenyl is substituted with R3a, R3b and R3c; and
(4) -CO-Ci-8alkyl, and
(5) -CONRl ORI I .
14. The compound of Claim 13 wherein R4 is hydrogen and R^ is selected from the group consisting of:
(1) Ci_8alkyl, which is unsubstituted or substituted with hydroxy,
(2) C3-iocycloalkyl,
(3) -CO-Ci-galkyl,
(4) tetrahydrofuranyl, which is unsubstituted or substituted with one or more Ci-galkyl, and (5) tetrahydropyranyl, which is unsubstituted or substituted with one or more Ci-galkyl.
15. The compound of Claim 14 wherein R4 is hydrogen and R5 is selected from the group consisting of:
(1) -CH2CH2C(CH3)3, (2) adamantyl,
(3) dimethyl-tetrahydrofuranyl, and (4) dimethyl-tetrahydropyranyl.
16. A compound which is selected from the group consisting of:
N- { [(3 S ,4R)-I -(3 ,3 -dimethylbutyl)-3 -fluoroρiperidin-4-yl]methyl} adamantane- 1 -carboxamide; 3,5-dichloro-N-{[(3S,4R)-l<33-dime1hylbu1yl)-3-fluoropiperidin-4-yl]metih.yl}benzainide;
3,5-dichloro-N-({(3S,4R)-l-[(3,3-dimethyltetrahydrofuran-2-yl)methyl3-3-fluoropiperidin-4- yl } methyl)benzamide;
3-chloro-N-{[(3S,4R)-l-(3,3-dimethyl-2-oxobutyl)-3-fluoropiperidin-4-yl]methyl}-5-methoxybenzamide;
3-chloro-N-({(3S,4R)-3-fluoro-l-[(2S)-2-hydroxy-3,3-dimethylbutyl]piperidin-4-yl}methyl)-5- methoxybenzamide;
3-chloro-N-( {(3 S,4R)-3-fluoro- 1 -[(2R)-2-hydroxy-3 ,3-dimethylbutyl]piperidin-4-yl}methyl)-5- methoxybenzamide;
N-({(3S,4R)-l-[2-(tert-butylamino)-2-oxoethyl]-3-fluoropiperidin-4-yl}methyl)-3,5-dichlorobenzamide;
3,5-dichloro-N-{[(3R,4R)-l-(3,3-dimethylbutyl)-3-fluoroρiperidm-4-yl]methyl}benzamide; 3,5-dimethyl-N-{[(3S,4R)-l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}benzamide;
3 ,5-dichloro-N-( { 1 -[(2,2-dimethyltetrahydro-2H-ρyran-4-yl)methyl]-3-fluoroρiρeridin-4- yl}methyl)benzamide;
N-ltl-Cl-adamantylmethy^-S-fluoropiperidin^-ylJmethyll-S^-dichlorobenzamide;
N-{[l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}adamantane-l-carboxamide; 3-chloro-N-{[l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-5-fluorobenzamide;
3 ,5 -dichloro-N- { [ 1 -(3 ,3 -dimethylbutyl)-3 -fluoropiperidin-4-yl]methyl } benzamide;
N-{[l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}adamantane-l-carboxamide;
N-({l-[(2,2-dimethyltetrahydro-2H-pyran-4-yl)methyl]-3-fluoropiperidin-4-yl}methyl)adamantane-l- carboxamide; 3,5 -methoxy-N- { [ 1 -(3 ,3 -dimethylbutyl)-3 -fluoropiperidin-4-yl]methyl}benzamide;
N-{[l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-3-fluoro-5-(trifluoromethyl)benzamide;
3-tert-butyl-N-{[l-(3,3-dxmethylbutyl)-3-fluoropiperidin-4-yl]methyl}-5-methoxybenzamide;
3 -chloro-N- { [ 1 -(3 ,3 -dimethylbutyl)-3 -fluoropiperidm-4-yl]methyI} benzamide;
3 -cyano-N- { [ 1 -(3 ,3-dimethylbutyl)-3 -fluoropiperidin-4-yl]methyl } -5 -fluorobenzamide; N-{[l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-3,5-difluorobenzamide;
N-{[l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-3-(trifluoromethoxy)benzamide;
N-ftl-CS^-dimethylbuty^-S-fluoropiperidin^-yymethyll-S-Cljl^^-tetrafluoroethoxy^enzaniide;
3,5-dibromo-N-{[l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}benzamide;
N- { [ 1 -(3 ,3 -dimethylbutyl)-3 -fluoroρiperidin-4-yl]methyl } -3 -(trifluoro)benzamide; 3 -(dimethylamino)-N- { [ 1 -(3 ,3 -dimethylbutyl)-3 -fluoropiperidin-4-yl]methyl}benzamide;
3 -brotno-N- { [ 1 -(3 ,3 -dimethylbutyl)-3 -fluoropiperidin-4-yl]methyl}benzamide; N- { [ 1 -(3 ,3 -dimethylbutyl)-3 -fluoropiperidin-4-yl]methyl} -3 -methylbenzamide;
N-{[l-(3,3-dimethylbutyl)-3-fluoropiperidm-4-yl]methyl}-l-(4-fluorophenyl)cyclohexanecarboxamide;
N-{[l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-l-(3-fluorophenyl)cyclopenanecarboxamide;
N- { [ 1 -(3 ,3 -dimethylbutyl)-3 -fluoropiperidin-4-yl]methyl} - 1 -(4-chlorophenyl)cyclobuanecarboxamide; N-{[l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-l-(4-chlorophenyl)cyclohexanecarboxamide;
N- { [ 1 -(3 ,3 -dimethylbutyl)-3 -fluoropiperidin-4-yl]methyl } - 1 -(4-methoxyphenyl)cyclopenane- carboxamide;
1 -(2-chloro-4-fluorophenyl)-N- { [ 1 -(3 ,3 -dimethylbutyl)-3 -fluoropiperidin-4-yl]methyl } cyclopentane- carboxamide; N-{[l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-l-(4-fluorophenyl)cyclopenanecarboxamide;
N-{[l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-l-(3-fluorophenyl)cyclohexanecarboxamide;
N- { [ 1 -(3 ,3 -dimethylbutyl)-3 -fluoropiperidin-4-yl]methyl} -1 -(4-methoxypheny. l)cyclohexane- carboxamide;
2-( 1 -adamantyl)-N- { [ 1 -(3 ,3 -dimethylbutyl)-3 -fluoropiperidin-4-yl]methyl} acetamide; 3,5-dichloro-N-{[(3R,4S)-l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}benzamide;
3,5-dichloro-N-({l-[(6,6-dimethyltetrahydro-2H-pyran-2-yl)methyl]-3-fluoropiperidin-4-yl}methyl)- benzamide;
3,5-dichloro-N-({l-[(3,3-dimethyltetrahydrofuran-2-yl)methyl]-3-fluoropiperidin-4-yl}methyl)- benzamide; N-{[(3S,4R)-l-(3,3-dimethylbutyl)-3-fluoropiperidm-4-yl]methyl}-3-fluoro-5-methoxybenzamide;
3-chloro-N-{[(3S,4R)-l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-5-
(trifluoromethyl)benzamide;
N-{[(3S,4R)-l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-3-methyl-5-
(trifluoromethyl)benzamide; N-{[(3S,4R)-l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-3-methoxy-5-methylbenzamide;
3-chloro-N-{[(3S,4R)-l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-5-methylbenzamide;
3-chloro-N- { [(3 S,4R)- 1 -(3 ,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl} -5-
(fluoromethoxy)benzamide;
3-chloro-N-({(3S,4R)-3-fluoro-l-[(2R)-2-hydroxy-3,3-dimethylbutyl]piperidin-4-yl}methyl)-5- methoxybenzamide;
3-chloro-N-({(3S,4R)-3-fluoro-l-[(2S)-2-hydroxy-3,3-dimethylbutyl]piperidin-4-yl}methyl)-5- methoxybenzamide;
3 -chloro-N- { [(3 S,4R)- 1 -(3,3 -dimethyl-2-oxobutyl)-3-fluoropiperidin-4-yl]methyl } -5 -methoxybenzamide;
4-chloro-N-{[(3S,4R)-l-(3,3-dimethylbutyl)-3-fluoropiperidm-4-yl]methyl}-3-fluorobenzamide; 3,5-dichloro-N-({(3S,4R)-3-fluoro-l-[(2R)-2-hydroxy-3,3-dimethylbutyl]piperidin-4- yl}methyl)benzamide; 3,5-dichloro-N-({(3S,4R)-3-fluoro-l-[(2S)-2-hydroxy-3;3-dimethylbutyl]piperidin-4- yl}methyl)benzamide;
3,5-dichloro-N-{[(3S,4R)-l-(3,3-dimethyl-2-oxobutyl)-3-fluoroρiperidin-4-yl]methyl}benzamide;
N-{[(3S,4R)-l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-3,5-dimethoxybenzamide; N-{[(3S,4R)-l-(3,3-dimethylbutyl)-3-fluoropiperidin-4-yl]methyl}-3-jEluoro-5-
(trifluoromethyl)benzamide;
N-({(3S,4R)-l-[2-(tert-butylamino)-2-oxoethyl]-3-fluoropiperidin-4-yl}methyl)-2-(4-tert- butylphenyl)acetamide;
N-[((3S,4R)-l-{2-[tert-butyl(2-methoxyethyl)amino]-2-oxoethyl}-3-fluoropiperidm-4-yl)methyl]-3,5- dichlorobenzamide;
3,5-dichloro-N-({(3S,4R)-3-fluoro-l-[2-(2-methylpiperidin-l-yl)-2-oxoethyl]piperidin-4- yl } methyl)benzamide;
3,5-dichloro-N-({(3S,4R)-l-[2-(4,4-dimethyl-l,3-oxazolidin-3-yl)-2-oxoethyl]-3-fluoropiperidin-4- yl}methyl)benzamide; N-[((3S,4R)-l-{2-[tert-butyl(ethyl)amino]-2-oxoethyl}-3-fluoropiperidin-4-yl)methyl]-3,5- dichlorobenzamide;
N-({(3S,4R)-l-[2-(tert-butylammo)-2-oxoethyl]-3-fluoropiperidin-4-yl}methyl)-3,5-dichlorobenzamide; or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition which comprises an inert carrier and a compound of
Claim 1 or a pharmaceutically acceptable salt thereof.
18. A method for treating or controlling epilepsy in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.
19. A method for treating or controlling pain in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.
20. A method for enhancing the quality of sleep in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.
PCT/US2006/024426 2005-06-23 2006-06-21 3-fluoro-piperidine t-type calcium channel antagonists WO2007002361A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2006262101A AU2006262101A1 (en) 2005-06-23 2006-06-21 3-fluoro-piperidine T-type calcium channel antagonists
US11/922,390 US20100222387A1 (en) 2005-06-23 2006-06-21 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists
JP2008518415A JP2008546800A (en) 2005-06-23 2006-06-21 3-Fluoropiperidine T-type calcium channel antagonist
EP06773826A EP1896414A4 (en) 2005-06-23 2006-06-21 3-fluoro-piperidine t-type calcium channel antagonists
CA002611153A CA2611153A1 (en) 2005-06-23 2006-06-21 3-fluoro-piperidine t-type calcium channel antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69350405P 2005-06-23 2005-06-23
US60/693,504 2005-06-23

Publications (2)

Publication Number Publication Date
WO2007002361A2 true WO2007002361A2 (en) 2007-01-04
WO2007002361A3 WO2007002361A3 (en) 2007-04-19

Family

ID=37595849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/024426 WO2007002361A2 (en) 2005-06-23 2006-06-21 3-fluoro-piperidine t-type calcium channel antagonists

Country Status (6)

Country Link
US (1) US20100222387A1 (en)
EP (1) EP1896414A4 (en)
JP (1) JP2008546800A (en)
AU (1) AU2006262101A1 (en)
CA (1) CA2611153A1 (en)
WO (1) WO2007002361A2 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054984A1 (en) * 2007-10-24 2009-04-30 Merck & Co., Inc. Heterocycle phenyl amide t-type calcium channel antagonists
US20090298883A1 (en) * 2008-06-02 2009-12-03 Hassan Pajouhesh N-piperidinyl acetamide derivatives as calcium channel blockers
EP2578573A1 (en) * 2010-05-24 2013-04-10 TOA Eiyo Ltd. Fused imidazole derivative
US8501773B2 (en) 2005-06-29 2013-08-06 Merck Sharp & Dohme Corp. 4-fluoro-piperidine T-type calcium channel antagonists
WO2014021383A1 (en) 2012-07-31 2014-02-06 協和発酵キリン株式会社 Condensed ring heterocyclic compound
CN103936663A (en) * 2013-01-23 2014-07-23 艾琪康医药科技（上海）有限公司 A preparation method of 1-R1-3, 3-difluoro (or 3-fluoro)-4-R2-4-aminomethylpiperidine and its derivatives
US8895551B2 (en) 2009-04-02 2014-11-25 Shionogi & Co., Ltd. Acrylamide compounds and the use thereof
US9000186B2 (en) 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
CN106459030A (en) * 2014-05-28 2017-02-22 东亚荣养株式会社 Substituted tropane derivatives
CN108289886A (en) * 2015-11-12 2018-07-17 安华赛公司 Ion channel inhibiting compound, pharmaceutical preparation and purposes
IL262216A (en) * 2008-06-02 2018-11-29 Taro Pharmaceuticals Inc N-piperidinyl acetamide derivatives as calcium channel blockers
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
US11130750B2 (en) 2017-02-15 2021-09-28 Cavion, Inc. Calcium channel inhibitors
US11273218B2 (en) 2015-10-22 2022-03-15 Cavion, Inc. Methods for treating Angelman syndrome and related disorders
US11311522B1 (en) 2018-10-03 2022-04-26 Cavion, Inc. Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
US11324733B2 (en) 2017-04-26 2022-05-10 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
US11427540B2 (en) 2019-07-11 2022-08-30 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113181187B (en) * 2021-06-03 2022-09-13 台州恩泽医疗中心(集团) Application of trifluoperazine in preparation of pharmaceutical composition for treating post-stroke cerebral edema

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3702324A (en) * 1970-06-24 1972-11-07 Stanford Research Inst 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines
MXPA04004674A (en) * 2001-11-14 2004-08-12 Schering Corp Cannabinoid receptor ligands.
WO2005123718A2 (en) * 2004-06-15 2005-12-29 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1896414A4 *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501773B2 (en) 2005-06-29 2013-08-06 Merck Sharp & Dohme Corp. 4-fluoro-piperidine T-type calcium channel antagonists
WO2009054984A1 (en) * 2007-10-24 2009-04-30 Merck & Co., Inc. Heterocycle phenyl amide t-type calcium channel antagonists
US8637513B2 (en) 2007-10-24 2014-01-28 Merck Sharp & Dohme Corp. Heterocycle phenyl amide T-type calcium channel antagonists
US9096522B2 (en) 2008-06-02 2015-08-04 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
EP2300007A4 (en) * 2008-06-02 2011-12-28 Zalicus Pharmaceuticals Ltd N-piperidinyl acetamide derivatives as calcium channel blockers
CN102695506A (en) * 2008-06-02 2012-09-26 扎里卡斯药品有限公司 N-piperidinyl acetamide derivatives as calcium channel blockers
EP3189839A1 (en) 2008-06-02 2017-07-12 Taro Pharmaceuticals Inc. N-piperidinyl acetamide derivatives as calcium channel blockers
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
EP3189839B1 (en) * 2008-06-02 2020-05-20 Praxis Precision Medicines, Inc. N-piperidinyl acetamide derivatives as calcium channel blockers
US8569344B2 (en) 2008-06-02 2013-10-29 Zalicus Pharmaceuticals Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US20140011996A1 (en) * 2008-06-02 2014-01-09 Zalicus Pharmaceuticals Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
KR20110025920A (en) * 2008-06-02 2011-03-14 잘리커스 파마슈티컬즈 리미티드 N-piperidinyl acetamide derivatives as calcium channel blockers
EP2300007A1 (en) * 2008-06-02 2011-03-30 Zalicus Pharmaceuticals Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
IL262216A (en) * 2008-06-02 2018-11-29 Taro Pharmaceuticals Inc N-piperidinyl acetamide derivatives as calcium channel blockers
KR101909749B1 (en) 2008-06-02 2018-10-18 타로 파마슈티컬즈 인코포레이티드 N-piperidinyl acetamide derivatives as calcium channel blockers
US20090298883A1 (en) * 2008-06-02 2009-12-03 Hassan Pajouhesh N-piperidinyl acetamide derivatives as calcium channel blockers
US8895551B2 (en) 2009-04-02 2014-11-25 Shionogi & Co., Ltd. Acrylamide compounds and the use thereof
US9096531B2 (en) 2010-05-24 2015-08-04 Toa Eiyo Ltd. Fused imidazole derivative
EP2578573A4 (en) * 2010-05-24 2014-08-06 Toa Eiyo Ltd Fused imidazole derivative
EP2578573A1 (en) * 2010-05-24 2013-04-10 TOA Eiyo Ltd. Fused imidazole derivative
US9000186B2 (en) 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
WO2014021383A1 (en) 2012-07-31 2014-02-06 協和発酵キリン株式会社 Condensed ring heterocyclic compound
CN103936663A (en) * 2013-01-23 2014-07-23 艾琪康医药科技（上海）有限公司 A preparation method of 1-R1-3, 3-difluoro (or 3-fluoro)-4-R2-4-aminomethylpiperidine and its derivatives
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
CN106459030A (en) * 2014-05-28 2017-02-22 东亚荣养株式会社 Substituted tropane derivatives
US9856250B2 (en) 2014-05-28 2018-01-02 Toa Eiyo Ltd. Substituted tropane derivatives
EP3150598A4 (en) * 2014-05-28 2018-01-03 TOA Eiyo Ltd. Substituted tropane derivatives
US11273218B2 (en) 2015-10-22 2022-03-15 Cavion, Inc. Methods for treating Angelman syndrome and related disorders
CN108289886A (en) * 2015-11-12 2018-07-17 安华赛公司 Ion channel inhibiting compound, pharmaceutical preparation and purposes
IL259199A (en) * 2015-11-12 2018-07-31 Afasci Inc Ion channel inhibitory compounds, pharmaceutical formulations and uses
EP3340988A4 (en) * 2015-11-12 2019-05-15 Afasci, Inc. Ion channel inhibitory compounds, pharmaceutical formulations and uses
CN108289886B (en) * 2015-11-12 2022-01-28 安华赛公司 Ion channel inhibiting compounds, pharmaceutical formulations and uses
US11130750B2 (en) 2017-02-15 2021-09-28 Cavion, Inc. Calcium channel inhibitors
US11324733B2 (en) 2017-04-26 2022-05-10 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
US11311522B1 (en) 2018-10-03 2022-04-26 Cavion, Inc. Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
US11427540B2 (en) 2019-07-11 2022-08-30 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof
US11649207B2 (en) 2019-07-11 2023-05-16 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof
US12077502B2 (en) 2019-07-11 2024-09-03 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof

Also Published As

Publication number Publication date
WO2007002361A3 (en) 2007-04-19
US20100222387A1 (en) 2010-09-02
JP2008546800A (en) 2008-12-25
AU2006262101A1 (en) 2007-01-04
CA2611153A1 (en) 2007-01-04
EP1896414A4 (en) 2009-09-09
EP1896414A2 (en) 2008-03-12

Similar Documents

Publication Publication Date Title
EP1901746B1 (en) 4-fluoro-piperidine t-type calcium channel antagonists
US20100222387A1 (en) 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists
EP2212291B1 (en) Heterocycle phenyl amide t-type calcium channel antagonists
EP2010493B1 (en) Pyridyl amide t-type calcium channel antagonists
EP1858520B1 (en) Quinazolinone t-type calcium channel antagonists
US20100249176A1 (en) Heterocycle amide t-type calcium channel antagonists
US20100216816A1 (en) Pyrazinyl amide-t type calcium channel antagonists
WO2011053542A1 (en) Heterocycle amide t-type calcium channel antagonists
US20100210671A1 (en) Quinazolinone T-Type Calcium Channel Antagonists
WO2011022315A1 (en) Pyrazinyl phenyl amide t-type calcium channel antagonists
EP2831071B1 (en) Imidazolyl methyl piperidine t-type calcium channel antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2611153

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006262101

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11922390

Country of ref document: US

Ref document number: 2006773826

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008518415

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006262101

Country of ref document: AU

Date of ref document: 20060621

Kind code of ref document: A